

---

---

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d) Securities Exchange Act of 1934 for the Quarterly Period ended December 31, 2017

-OR-

Transition Report Pursuant to Section 13 or 15(d) of the Securities And Exchange Act of 1934 for the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: **000-54717**

**BIONIK LABORATORIES CORP.**

(Exact name of Registrant in its charter)

**Delaware**

(State or Other Jurisdiction of Incorporation or Organization)

**27-1340346**

(I.R.S. Employer Identification Number)

**483 Bay Street, N105  
Toronto, Ontario**

(Address of Principal Executive Offices)

**M5G 2C9**

(Zip Code)

Registrant's Telephone Number, Including Area Code: **(416) 640-7887**

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company as defined by Rule 12b-2 of the Exchange Act):

Large accelerated filer	<input type="checkbox"/>	Non-accelerated filer	<input type="checkbox"/>
Accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Indicate the number of shares outstanding of each of the registrant's classes of common stock, as of the latest practicable date. As of February 13, 2018, 55,885,279 shares of Common Stock, par value \$0.001 per share.

---

---

**BIONIK LABORATORIES CORP.  
FORM 10-Q**

**INDEX**

	<u>Page</u>
<b><u>PART I – FINANCIAL INFORMATION</u></b>	
<u>Item 1. Financial Statements</u>	<u>1</u>
<u>Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>20</u>
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	<u>25</u>
<u>Item 4. Controls and Procedures</u>	<u>26</u>
<b><u>PART II - OTHER INFORMATION</u></b>	
<u>Item 1. Legal Proceedings</u>	<u>26</u>
<u>Item 1A. Risk Factors</u>	<u>26</u>
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>26</u>
<u>Item 3. Defaults Upon Senior Securities</u>	<u>26</u>
<u>Item 4. Mine Safety Disclosures</u>	<u>26</u>
<u>Item 5. Other Information</u>	<u>26</u>
<u>Item 6. Exhibits</u>	<u>26</u>
<u>SIGNATURES</u>	<u>27</u>

**PART I – FINANCIAL INFORMATION**  
**Item 1. Financial Statements**

**UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**December 31, 2017 and 2016**

**Index**

	<u>Page</u>
<a href="#"><u>Unaudited Condensed Consolidated Interim Financial Statements</u></a>	<u>1</u>
<a href="#"><u>Condensed Consolidated Interim Balance Sheets as at December 31, 2017 (Unaudited) and March 31, 2017</u></a>	<u>2</u>
<a href="#"><u>Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) for the three and nine month Periods ended December 31, 2017 and 2016</u></a>	<u>3</u>
<a href="#"><u>Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Deficiency) for the nine month period ended December 31, 2017 and year ended March 31, 2017 (Unaudited)</u></a>	<u>4</u>
<a href="#"><u>Condensed Consolidated Interim Statements of Cash Flows for the nine month periods ended December 31, 2017 and 2016 (Unaudited)</u></a>	<u>5</u>
<a href="#"><u>Notes to Condensed Consolidated Interim Financial Statements (Unaudited)</u></a>	<u>6-19</u>

**Bionik Laboratories Corp.**  
**Condensed Consolidated Interim Balance Sheets**  
(Amounts expressed in US Dollars)

	As at December 31, 2017 (Unaudited) \$	As at March 31, 2017 (Note 2) \$
<b>Assets</b>		
<b>Current</b>		
Cash and cash equivalents	998,661	543,650
Accounts receivable, net of allowance for doubtful accounts of \$16,349 (March 31, 2017 - \$10,000)	306,572	383,903
Prepaid expenses and other receivables (Note 5)	145,044	228,047
Inventories (Note 6)	302,414	228,249
Due from related parties (Note 9(a))	19,374	18,731
<b>Total Current Assets</b>	<b>1,772,065</b>	<b>1,402,580</b>
Equipment (Note 7)	174,997	227,421
Technology and other assets (Note 4)	4,783,704	5,030,624
Goodwill (Note 4)	22,308,275	22,308,275
<b>Total Assets</b>	<b>29,039,041</b>	<b>28,968,900</b>
<b>Liabilities and Shareholders' Deficiency</b>		
<b>Current</b>		
Accounts Payable (Notes 9(b))	794,875	784,771
Accrued liabilities (Notes 3, 8 and 9(b))	1,868,225	1,228,657
Customer advances	800	121,562
Demand Notes Payable (Note 8(a))	50,000	330,600
Promissory Notes payable (Note 8(b))	-	236,548
Convertible Loans Payable (Note 8(d), (e) and (f))	7,079,852	2,017,488
Short term loan (Note 8(c))	400,000	-
Deferred revenue	113,801	98,624
<b>Total Current Liabilities</b>	<b>10,307,553</b>	<b>4,818,250</b>
<b>Shareholders' Equity</b>		
Preferred Stock, par value \$0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value \$0.001; Authorized; Issued and outstanding - 1 (March 31, 2017 - 1)	-	-
Common Shares, par value \$0.001; Authorized - 250,000,000 (March 31, 2017 - 150,000,000); Issued and outstanding 55,885,279 and 45,909,336 Exchangeable Shares (March 31, 2017 - 48,885,107 and 47,909,336 Exchangeable Shares) (Note 10)	101,794	96,794
Additional paid in capital	48,081,670	45,088,171
Shares to be issued (Note 10)	60,000	-
Deficit	(29,554,125)	(21,076,464)
Accumulated other comprehensive income	42,149	42,149
<b>Total Shareholders' Equity</b>	<b>18,731,488</b>	<b>24,150,650</b>
<b>Total Liabilities and Shareholders' Equity</b>	<b>29,039,041</b>	<b>28,968,900</b>

Going Concern (Note 1)

Commitments and Contingencies (Note 13)

Subsequent Events (Note 15)

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

**Bionik Laboratories Corp.****Condensed Consolidated Interim Statements of Operations and Comprehensive Loss for the three and nine months periods ended December 31, 2017 and 2016 (unaudited)**

(Amounts expressed in U.S. Dollars)

	<b>Three months ended Dec. 31, 2017</b>	<b>Nine months ended Dec. 31, 2017</b>	<b>Three months ended Dec. 31, 2016</b>	<b>Nine months ended Dec. 31, 2016</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
			<b>(Note 2)</b>	<b>(Note 2)</b>
Sales	260,960	570,327	372,426	553,900
Cost of Sales	88,357	177,482	334,786	405,680
Gross Margin	<u>172,603</u>	<u>392,845</u>	<u>37,640</u>	<u>148,220</u>
<b>Operating expenses</b>				
Sales and marketing	432,260	1,313,077	377,046	646,509
Research and development	546,350	1,947,659	571,671	1,803,234
General and administrative	783,784	2,916,917	409,669	2,291,136
Share compensation expense (Note 11)	271,001	1,284,257	227,540	651,630
Convertible debt accretion (Note 8)	216,302	290,375	-	-
Amortization (Note 4)	76,985	246,920	-	-
Depreciation (Note 7)	21,234	69,606	24,028	57,781
Total operating expenses	<u>2,347,916</u>	<u>8,068,811</u>	<u>1,609,954</u>	<u>5,450,290</u>
<b>Other expenses (income)</b>				
Foreign Exchange	(11,485)	102,671	-	-
Interest expense (Note 8)	416,990	657,350	13,808	23,839
Other income	(59)	649	(4,363)	(410,877)
Total other expenses (income)	<u>405,446</u>	<u>760,670</u>	<u>9,445</u>	<u>(387,038)</u>
<b>Net loss and comprehensive loss for the period</b>	<u>(2,580,759)</u>	<u>(8,436,636)</u>	<u>(1,581,759)</u>	<u>(4,915,032)</u>
Loss per share – basic	<u>(0.03)</u>	<u>\$ (0.08)</u>	<u>(0.02)</u>	<u>(0.05)</u>
Loss per share – diluted	<u>(0.03)</u>	<u>\$ (0.08)</u>	<u>\$ (0.02)</u>	<u>\$ (0.05)</u>
Weighted average number of shares outstanding – basic	<u>101,794,615</u>	<u>99,335,514</u>	<u>96,362,541</u>	<u>90,286,864</u>
Weighted average number of shares outstanding – diluted	<u>101,794,615</u>	<u>99,335,514</u>	<u>96,362,541</u>	<u>90,286,864</u>

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements

**Bionik Laboratories Corp.**

**Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Deficiency) for the nine month period ended December 31, 2017 and the year ended March 31, 2017 (unaudited)**

(Amounts expressed in US Dollars)

	Special Voting Preferred Stock		Common Stock (1)		Additional Paid in Capital	Shares to be Issued	Deficit	Comprehensive Income	Total
	Shares	Amount	Shares	Amount					
		\$		\$					
			(Note 2)	(Note 2)	(Note 2)		(Note 2)		(Note 2)
<b>Balance, March 31, 2016</b>	<b>1</b>	<b>-</b>	<b>72,591,292</b>	<b>72,591</b>	<b>18,292,173</b>	<b>-</b>	<b>(13,007,062)</b>	<b>42,149</b>	<b>5,399,851</b>
Shares issued to acquire IMT	-	-	23,650,000	23,650	23,153,350	-	-	-	23,177,000
Share compensation acquired	-	-	-	-	2,582,890	-	-	-	2,582,890
Options exercised	-	-	110,096	110	18,056	-	-	-	18,166
Cashless exercise of warrants	-	-	51,249	51	(51)	-	-	-	-
Warrants exercised	-	-	174,759	175	40,020	-	-	-	40,195
Share compensation expense	-	-	217,047	217	1,001,733	-	-	-	1,001,950
Net loss for the year	-	-	-	-	-	-	(8,069,402)	-	(8,069,402)
<b>Balance, March 31, 2017</b>	<b>1</b>	<b>-</b>	<b>96,794,443</b>	<b>96,794</b>	<b>45,088,171</b>	<b>-</b>	<b>(21,076,464)</b>	<b>42,149</b>	<b>24,150,650</b>
Warrants exercised	-	-	5,000,172	5,000	1,120,038	-	-	-	1,125,038
Share compensation expense	-	-	-	-	1,284,257	-	-	-	1,284,257
Fair value of warrants on convertible loans	-	-	-	-	548,179	-	-	-	548,179
Warrant down round feature (Note 12)	-	-	-	-	41,025	-	(41,025)	-	-
Shares to be issued	-	-	-	-	-	60,000	-	-	60,000
Net loss for the period	-	-	-	-	-	-	(8,436,636)	-	(8,436,636)
<b>Balance, December 31, 2017</b>	<b>1</b>	<b>-</b>	<b>101,794,615</b>	<b>101,794</b>	<b>48,081,670</b>	<b>60,000</b>	<b>(29,544,125)</b>	<b>42,149</b>	<b>18,731,488</b>

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements

(1) Includes exchangeable shares

**Bionik Laboratories Corp.****Condensed Consolidated Interim Statements of Cash Flows for the nine months periods ended December 31, 2017 and 2016****(unaudited)**

(Amounts expressed in U.S. Dollars)

	Nine months ended December 31, 2017 \$	Nine months ended December 31, 2016 \$ (Note 2)
<b>Operating activities</b>		
Net loss for the period	(8,436,636)	(4,915,032)
Adjustment for items not affecting cash		
Depreciation	69,606	57,781
Amortization	246,920	-
Interest expense	640,168	23,839
Share based compensation expense	1,284,257	592,130
Convertible debt accretion	290,375	-
Shares issued for services	60,000	59,500
Allowance for doubtful accounts	(16,349)	-
	<u>(5,861,659)</u>	<u>(4,181,782)</u>
Changes in non-cash working capital items		
Accounts receivable	93,680	(247,359)
Prepaid expenses and other receivables	83,003	95,562
Due from related parties	(643)	532
Inventories	(74,165)	(120,894)
Accounts payable	10,104	(720,573)
Accrued liabilities	639,568	(492,047)
Customer advances	(120,762)	28,000
Deferred revenue	15,177	97,615
<b>Net cash used in operating activities</b>	<u>(5,215,697)</u>	<u>(5,540,946)</u>
<b>Investing activities</b>		
Acquisition of equipment	(17,182)	(9,827)
<b>Net cash used in investing activities</b>	<u>(17,182)</u>	<u>(9,827)</u>
<b>Financing activities</b>		
Proceeds from convertible loans	4,699,975	483,333
Proceeds on exercise of warrants	1,125,038	-
Repayment of Promissory note principal	(200,000)	-
Repayment of Promissory note interest	(49,505)	-
Repayment of Demand notes principal	(208,359)	-
Repayment of Demand notes interest	(79,259)	-
Proceeds from short term loan	400,000	-
Cash acquired on acquisition	-	266,635
<b>Net cash provided by financing activities</b>	<u>5,687,890</u>	<u>749,968</u>
Net decrease in cash and cash equivalents for the period	455,011	(4,800,805)
Cash and cash equivalents, beginning of period	543,650	5,381,757
<b>Cash and cash equivalents, end of period</b>	<u>998,661</u>	<u>580,952</u>

**Supplemental Information:**

Assets acquired and liabilities assumed as at April 21, 2016:

Current assets, including cash of \$266,635	478,843
Equipment	59,749
Intangible assets	5,580,704
Goodwill	22,308,275
Accounts payable	(241,299)
Accrued liabilities	(361,029)
Customer deposits	(86,487)
Demand notes payable	(324,894)
Promissory Notes payable	(217,808)
Bionik advance	(1,436,164)
Non-cash consideration	<u>25,759,890</u>

Interest paid or settled (Note 8(a) and (b))

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.





**BIONIK LABORATORIES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**For the three and nine month periods ended December 31, 2017 and 2016 (unaudited)**

**(Amounts expressed in U.S. Dollars)**

**1. NATURE OF OPERATIONS AND GOING CONCERN**

**The Company and its Operations**

Bionik Laboratories Corp. (the “Company” or “Bionik”) was incorporated on January 8, 2010 in the State of Colorado as Strategic Dental Management Corp. On July 16, 2013 the Company changed its name to Drywave Technologies Inc. (“Drywave”) and its state of incorporation from Colorado to Delaware. Effective February 13, 2015, the Company changed its name to Bionik Laboratories Corp. and reduced the authorized number of shares of common stock from 200,000,000 to 150,000,000. Concurrently, the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014.

On February 26, 2015, the Company entered into a Share Exchange Agreement and related transactions whereby it acquired Bionik Laboratories Inc., a Canadian Corporation (“Bionik Canada”). Bionik Canada issued 50,000,000 Exchangeable Shares, representing a 3.14 exchange ratio, for 100% of the then outstanding common shares of Bionik Canada (the “Merger”). The Exchangeable Shares are exchangeable at the option of the holder, each into one share of the common stock of the Company. In addition the Company issued one Special Preferred Voting Share (the “Special Preferred Share”) (Note 10).

As a result of the shareholders of Bionik Canada having a controlling interest in the Company subsequent to the Merger, for accounting purposes the Merger does not constitute a business combination. The transaction has been accounted for as a recapitalization of the Company with Bionik Canada being the accounting acquirer even though the legal acquirer is Bionik, accordingly, the historic financial statements of Bionik Canada are presented as the comparative balances for the period prior to the Merger.

References to the Company refer to the Company and its wholly owned subsidiaries, Bionik Acquisition Inc. and Bionik Canada. References to Drywave relate to the Company prior to the Merger.

On April 21, 2016, the Company acquired all of the outstanding shares and, accordingly, all assets and liabilities of Interactive Motion Technologies, Inc. (“IMT”), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic products for neurorehabilitation, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated March 1, 2016, with IMT, Hermano Igo Krebs, and Bionik Mergerco Inc., a Massachusetts corporation and the Company’s wholly owned subsidiary (“Bionik Mergeco”). The merger agreement provided for the merger of Bionik Mergerco with and into IMT, with IMT surviving the merger as the Company’s wholly owned subsidiary. In return for acquiring IMT, IMT shareholders received an aggregate of 23,650,000 shares of the Company’s common stock.

Bionik Laboratories Corp. is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility impaired individuals, including three products in the market and four products in varying stages of development. The InMotion Systems - the InMotion ARM, In Motion Wrist, InMotion Hand – are designed to provide intelligent, adaptive therapy in a manner that has been clinically verified to maximize neuro-recovery. Bionik also has a lower-body exoskeleton - the ARKE - designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking. The Company is developing with a partner a lower body product based on some of the ARKE technology, which should allow certain individuals to walk better, who have limited mobility. This product is expected to be launched in the consumer home market.

The unaudited condensed consolidated interim financial statements consolidate the Company and its wholly owned subsidiaries Bionik Canada, Bionik Acquisition Inc. and Bionik, Inc. (the former IMT) since its acquisition on April 21, 2016.

These unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which contemplates continuation of the Company as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business.

The Company’s principal offices are located at 483 Bay Street, N105, Toronto, Ontario, Canada M5G 2C9 and its U.S. address is 80 Coolidge Hill Road, Watertown, MA. USA 02472.

**Going Concern**

As at December 31, 2017, the Company had a working capital deficit of \$8,535,488 (March 31, 2017 - \$3,415,670) and an accumulated deficit of \$29,554,125 (March 31, 2017 - \$21,076,464) and the Company incurred a net loss and comprehensive loss of (\$8,436,636) for the nine months period ended December 31, 2017 (December 31, 2016 – \$(4,915,032)).

There is no certainty that the Company will be successful in generating sufficient cash flow from operations or achieving and maintaining profitable operations in the future to enable it to meet its obligations as they come due and consequently continue as a going concern. The Company will require additional financing this year to fund its operations and it is currently working on securing this funding through the issuance of convertible promissory notes, corporate collaborations, public or private equity offerings or debt financings. Sales of additional equity or equity linked securities by the Company would result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required. In the event that the necessary additional financing is not obtained, the Company would reduce its discretionary overhead costs substantial or otherwise curtail operations.



**BIONIK LABORATORIES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**For the three and nine month periods ended December 31, 2017 and 2016 (unaudited)**

(Amounts expressed in U.S. Dollars)

**1. NATURE OF OPERATIONS AND GOING CONCERN (continued)**

The Company expects the forgoing, or a combination thereof, to meet the Company's anticipated cash requirements for the next 12 months; however, these conditions raise substantial doubt about the Company's ability to continue as a going concern. The accompanying condensed consolidated interim financial statements do not include any adjustments to reflect the possible future effects on recoverability and reclassification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

The condensed consolidated interim financial statements do not include any adjustments related to the recoverability and classification of the recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. All adjustments, consisting only of normal recurring items, considered necessary for fair presentation have been included in these condensed consolidated interim financial statements.

**2. CHANGE IN ACCOUNTING POLICY**

The FASB issued ASU No. 2017-11, *Earnings Per Share (Topic 260) Distinguishing Liabilities From Equity (Topic 480) Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments With Down Round Features II Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception*, allows a financial instrument with a down-round feature to no longer automatically be classified as a liability solely based on the existence of the down-round provision. The update also means the instrument would not have to be accounted for as a derivative and be subject to an updated fair value measurement each reporting period.

On consideration of the above factors, the Company elected to early adopt ASU 2017-11 on July 1, 2017, the ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other organizations, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020.

The early adoption allows the Company to reduce the cost and complexity of updating the fair value measurement each reporting period and eliminate the unnecessary volatility in reported earnings created by the revaluation when the Company's shares' value changes.

The Company presented the change in accounting policy through the retrospective application of the new accounting principle to all prior periods, as described in ASU No. 250-10-45-5, Accounting Changes and Error Corrections.

The following financial statement line items for the periods indicated were affected by the change in accounting principle.

**Income statement**

	Three months period ended December 2016			Nine months period ended December 2016		
	As originally reported	As adjusted	Effect of change	As originally reported	As adjusted	Effect of change
Sales	\$ 372,426	\$ 372,426	\$ -	\$ 553,900	\$ 553,900	\$ -
Cost of Sales	334,786	334,786	-	405,680	405,680	-
Total operating expenses	1,609,954	1,609,954	-	5,450,290	5,450,290	-
Total other expenses	(761,896)	9,445	(771,341)	(2,897,426)	(387,038)	2,510,388
Net income (loss) and comprehensive loss for the period	(810,418)	(1,581,759)	(771,341)	(2,404,644)	(4,915,032)	(2,510,388)
Net income (loss) per share	(0.01)	(0.02)	(0.01)	(0.03)	(0.05)	(0.02)

**BIONIK LABORATORIES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**For the three and nine month periods ended December 31, 2017 and 2016 (unaudited)**

(Amounts expressed in U.S. Dollars)

**Balance sheet**

	<b>As at March 31, 2017</b>		
	<b>As originally reported</b>	<b>As adjusted</b>	<b>Effect of change</b>
Current assets	\$ 1,402,580	\$ 1,402,580	\$ -
Capital assets	227,421	227,421	-
Intangible assets	27,338,899	27,338,899	-
Total assets	<u>28,968,900</u>	<u>28,968,900</u>	-
Warrant derivative liability	959,600	-	(959,600)
Other current liabilities	4,818,205	4,818,250	45
Total liabilities	<u>5,777,805</u>	<u>4,818,250</u>	<u>(959,555)</u>
Common stock	96,794	96,794	-
Additional paid in capital	38,640,706	45,088,171	6,447,465
Retained earnings	(15,588,554)	(21,076,464)	(5,487,910)
Accumulated other comprehensive income	42,149	42,149	-
Total shareholders' equity	<u>23,191,095</u>	<u>24,150,650</u>	<u>959,555</u>
Total liabilities and shareholders' equity	<u>28,968,900</u>	<u>29,968,900</u>	-

The change in retained earnings consists of a change in net loss for the year ended March 31 2017, changing from \$3,936,574 to \$8,069,402, a net change of \$4,132,828. The remainder of the change included in the \$5,487,910 noted above relates to periods prior to March 31, 2016.

**Statement of cash flows**

	<b>As at December 31, 2016</b>		
	<b>As originally reported</b>	<b>As adjusted</b>	<b>Effect of change</b>
Net loss for the period	\$ (2,404,644)	\$ (4,915,032)	\$ (2,510,388)
Adjustment for items not affecting cash			
Depreciation	57,781	57,781	
Interest expense	23,839	23,839	
Share-based compensation expense	592,130	592,130	
Shares issued for service	59,500	59,500	
Change in fair value of warrant derivative liability	(2,510,388)	-	2,510,388
Change in non-cash working capital items	(1,359,164)	(1,359,164)	
Net cash used in operating activities	<u>(5,540,946)</u>	<u>(5,540,946)</u>	-
Net cash used in investing activities	(9,827)	(9,827)	-
Net cash provided by financing activities	749,968	749,968	-
Net decrease in cash and cash equivalents for the period	(4,800,805)	(4,800,805)	-
Cash and cash equivalents, beginning of period	5,381,757	5,381,757	-
Cash and cash equivalents, end of period	<u>580,952</u>	<u>580,952</u>	-

**BIONIK LABORATORIES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**For the three and nine month periods ended December 31, 2017 and 2016 (unaudited)**

**(Amounts expressed in U.S. Dollars)**

**3. SIGNIFICANT ACCOUNTING POLICIES**

**Unaudited Condensed Consolidated Interim Financial Statements**

These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements of the Company and should be read in conjunction with those annual audited financial statements filed on Form 10-K for the year ended March 31, 2017. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company's financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.

**Newly Adopted and Recently Issued Accounting Pronouncements**

In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)". The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. For a public entity, early adoption is not permitted. The impact on the condensed consolidated interim financial statements of adopting ASU 2014-09 will be assessed by management.

In November 2015, the FASB issued ASU No. 2015-17, "Balance Sheet Classification of Deferred Taxes," which requires that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company does not anticipate that the adoption of ASU No. 2015-17 will have a material effect on the condensed consolidated interim financial position or the consolidated results of operations.

In January 2016, the FASB issued ASU No. 2016-01 "Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities". The updates makes several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company is still assessing the impact that the adoption of ASU 2016-01 will have on the condensed consolidated interim financial position and the consolidated results of operations.

In February 2016, the FASB issued ASU 2016-02, "Leases". This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the condensed consolidated interim financial position and the consolidated results of operations.

In March 2016, the FASB issued ASU 2016-09, "Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting". Several aspects of the accounting for share-based payment award transaction are simplified, including (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company has adopted this policy during the period and there was no impact on the condensed consolidated interim financial statements.

In August 2016, the FASB issued ASU 2016-15, "Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments". This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company is still assessing the impact that the adoption of ASU 2016-15 will have on the condensed consolidated interim statement of cash flows.

In January 2017, the FASB issued ASU 2017-01, "Business Combinations: Clarifying the definition of a Business" which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquired is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term "outputs" to be consistent with how it described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date.

In January 2017, the FASB issued ASU 2017-04, "Intangibles – Goodwill and Other" ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit's carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019.

In September 2017, the FASB issued ASU 2017-13, "Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic

606), Leases (Topic 840), and Leases (Topic 842)". ASU 2017-13 amends the early adoption date option for certain companies related to the adoption of ASU 2014-09 and ASU 2016-02. The Company is not early adopting this standard; however, we are currently assessing the impact that the eventual adoption of this standard will have on the Company.

**BIONIK LABORATORIES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**For the three and nine month periods ended December 31, 2017 and 2016 (unaudited)**

**(Amounts expressed in U.S. Dollars)**

**3. SIGNIFICANT ACCOUNTING POLICIES (continued)**

**Revenue Recognition**

The Company recognizes revenue from product sales when persuasive evidence of an agreement with customer exists, products are shipped or title passes pursuant to the terms of the agreement, the amount due from the customer is fixed or determinable, collectability is reasonably assured, and there are no significant future performance obligation. Deposits are carried as liabilities until the requirements for revenue recognition are met.

**Warranty Reserve and Deferred Warranty Revenue**

The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the balance sheet and amounted to \$64,957 at December 31, 2017 and March 31, 2017. The Company also sells extended warranties of or additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized \$Nil of expense related to the change in warranty reserves and warranty costs incurred and recorded as an expense in cost of goods sold during the three and nine month period ended December 31, 2017 (December 31, 2016 - \$15,355 and \$30,732, respectively).

**Foreign Currency Translation**

The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.

**Fair Value of Financial Instruments**

ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expand disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs which are as observable as possible and the methods most applicable to the specific situation of each company or valued item.

The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, other receivables, accounts payable and accrued liabilities, due from related parties, demand notes payable, promissory notes payable, convertible notes payable, and short-term loans approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

The Company's policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the period.

**BIONIK LABORATORIES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**For the three and nine month periods ended December 31, 2017 and 2016 (unaudited)**

(Amounts expressed in U.S. Dollars)

**4. ACQUISITION**

On April 21, 2016, the Company acquired 100% of the common and preferred shares of IMT, through a transaction where Bionik Mergerco merged with and into IMT, with IMT surviving the merger as a wholly owned subsidiary of Bionik. Bionik issued an aggregate of 23,650,000 shares of Company Common Stock in exchange for all shares of IMT Common Stock and IMT Preferred Stock outstanding immediately prior to April 21, 2016. All shares have been issued at March 31, 2017.

Bionik also assumed each of the 3,895,000 options to acquire IMT Common Stock granted under IMT's equity incentive plan or otherwise issued by IMT. These options were exchanged for purchase of an aggregate of 3,000,000 shares of Company Common Stock, of which 1,000,000 have an exercise price of \$0.25. 1,000,000 have an exercise price of \$0.95 and 1,000,000 have an exercise price of \$1.05. Stock compensation expense on vested options of \$2,582,890 was recorded on the options exchanged and this amount is included in the acquisition equation.

As a result of the acquisition of IMT, the Company acquired assets including three licensed patents, two license agreements, three FDA listed products, an FDA inspected manufacturing facility, extensive clinical and sales data, and international distributors. The Company retained an independent valuator to determine the purchase price allocation, which reflects the allocation of assets and goodwill. The following sets forth the purchase price allocation based on management's best estimates of fair value, including a summary of major classes of consideration transferred and the recognized amounts of assets acquired and liabilities assumed at the acquisition date.

	<b>As at April 21, 2016 \$</b>
Fair value of 23,650,000 shares of common stock (a)	23,177,000
Fair value of vested stock options (b)	2,582,890
<b>Allocation of purchase price:</b>	<u>25,759,890</u>
Cash and cash equivalents	266,635
Accounts receivable	6,490
Inventories	188,879
Prepaid expenses and other current assets	16,839
Equipment	59,749
<b>Liabilities assumed:</b>	
Accounts payable	(241,299)
Accrued liabilities	(361,029)
Customer deposits	(86,487)
Demand notes payable	(324,894)
Promissory notes payable	(217,808)
Bionik advance (c)	<u>(1,436,164)</u>
Net assets acquired	(2,129,089)
Patents and exclusive License Agreement	1,306,031
Trademark	2,505,907
Customer relationships	1,431,680
Non compete agreement	61,366
Assembled Workforce	275,720
Goodwill	22,308,275
	<u>25,759,890</u>

- (a) The fair value of common stock was based on \$0.98, which was the closing market price of the Company's common stock on April 21, 2016.
- (b) The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59%, dividend and forfeiture rates of 0% and expected volatility of 114% which is consistent with the Company's assumptions (Note 11).
- (c) Included in the net assets acquired was a loan issued to IMT in the amount of \$300,000 under normal commercial terms. The loan carried an interest rate of 6% and were secured by all the assets of IMT subject to a \$200,000 subordination to a third party financial services company, which was released in April 2016.



**BIONIK LABORATORIES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**For the three and nine month periods ended December 31, 2017 and 2016 (unaudited)**

(Amounts expressed in U.S. Dollars)

**4. ACQUISITION (continued)**

The schedule below reflects the intangible assets acquired in the IMT acquisition and the assets amortization period and expense for the three and nine months period ended December 31, 2017 and the year ended March 31, 2017:

Intangible assets acquired	Amortization period (years)	Value acquired \$	Expense	Value at	3 Months	9 Months	Value at
			March 31, 2017 \$	March 31, 2017 \$	Expense December 31, 2017 \$	Expense December 31, 2017 \$	December 31, 2017 \$
Patents and exclusive License Agreement	9.74	1,306,031	126,375	1,179,656	33,522	100,604	1,079,052
Trademark	Indefinite	2,505,907	-	2,505,907	-	-	2,505,907
Customer relationships	10	1,431,680	134,931	1,296,749	35,792	107,414	1,189,335
Non compete agreement	2	61,366	28,918	32,448	7,671	23,038	9,410
Assembled Workforce	1	275,720	259,856	15,864	-	15,864	-
		<u>5,580,704</u>	<u>550,080</u>	<u>5,030,624</u>	<u>76,985</u>	<u>246,920</u>	<u>4,783,704</u>

**5. PREPAID EXPENSES AND OTHER RECEIVABLES**

	December 31, 2017 \$	March 31, 2017 \$
Prepaid expenses and sundry receivables	52,221	68,484
Prepaid insurance	70,165	136,896
Sales taxes receivable (i)	22,658	22,667
	<u>145,044</u>	<u>228,047</u>

(i) Represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

**6. INVENTORIES**

	December 31, 2017 \$	March 31, 2017 \$
Raw materials	264,334	119,985
Work in progress	14,283	108,264
Finished Goods	23,797	-
	<u>302,414</u>	<u>228,249</u>

**7. EQUIPMENT**

Equipment consisted of the following as at December 31, 2017 and March 31, 2017:

	December 31, 2017			March 31, 2017		
	Cost	Accumulated Depreciation	Net	Cost	Accumulated Depreciation	Net
	\$	\$	\$	\$	\$	\$
Computers and electronics	252,120	219,288	32,832	250,538	204,258	46,280
Furniture and fixtures	36,795	27,598	9,197	36,795	26,096	10,699
Demonstration equipment	200,186	92,539	107,647	184,586	44,420	140,166
Manufacturing equipment	88,742	85,509	3,233	88,742	84,982	3,760
Tools and parts	11,422	5,447	5,975	11,422	4,472	6,950
Assets under capital lease	23,019	6,906	16,113	23,019	3,453	19,566
	<u>612,284</u>	<u>437,287</u>	<u>174,997</u>	<u>595,102</u>	<u>367,681</u>	<u>227,421</u>

Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the three and nine months period ended December 31, 2017 was \$21,234 and \$69,606 (December 31, 2016 - \$24,028 and \$57,781).

**BIONIK LABORATORIES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**For the three and nine month periods ended December 31, 2017 and 2016 (unaudited)**

(Expressed in U.S. Dollars)

**8. NOTES PAYABLE**

**(a) Demand Notes payable**

The Company repaid on December 31, 2017, all outstanding demand notes payable (“Notes”) except Notes in the aggregate principal amount of \$50,000, which was deferred to June 30, 2018 acquired from IMT on April 21, 2016.

<b>Balance, March 31, 2017</b>	330,600
Accrued interest	7,018
Repayment of principal	(208,359)
Repayment of interest	(79,259)
<b>Balance, December 31, 2017</b>	<b>\$ 50,000</b>

Interest expense incurred on the Notes totaled \$2,309 and \$7,018 for the three months and nine months periods ended December 31, 2017 (December 31, 2016 - \$2,367 and \$3,467), which is included in accrued liabilities.

**(b) Promissory Notes payable**

In February 2014, the Company borrowed \$200,000 from an existing investor under the terms of a secured promissory note (“Promissory Note”). The Promissory Note bore interest at a simple interest rate equal to 10% per annum and interest is payable quarterly. Interest expenses incurred on the Promissory Note totaled \$3,059 and \$12,957 for the three and nine months ended December 31, 2017 (December 31, 2016 - \$5,041 and \$13,973). The Promissory Note was paid in full during the quarter.

<b>Balance, March 31, 2017</b>	236,548
Accrued interest	12,957
Repayment of principal	(200,000)
Repayment of interest	(49,505)
<b>Balance, December 31, 2017</b>	<b>\$ -</b>

**(c) Short term Loan**

In December 2017, a company controlled by a Board member made a short-term loan to the Company of \$400,000 with interest at 1.5% per month. Interest expenses incurred on the loan totaled \$2,400 for the three and nine months ended December 31, 2017 (December 31, 2016 - \$Nil and \$Nil). The Company repaid this loan with interest of \$3,200 in January 2018.

**(d) Convertible Loans Payable**

In December 2016, several shareholders of the Company agreed to advance the Company \$1,500,000 of convertible notes in three tranches: \$500,000 upon origination of the convertible loans and \$500,000 on each of January 15, 2017 and February 15, 2017. A further \$500,000 was advanced in March 2017 to bring the total of these convertible loans to approximately \$2,000,000. The convertible loans bore interest at 6% until the original due date of March 31, 2017 and \$17,488 was accrued and expensed as interest on these loans for the year ended March 31, 2017.

The convertible loans contain the following terms: convertible at the option of the holder at the price of the equity financing or payable on demand upon the completion of an equity financing greater than \$5,000,000; automatically convertible at the price of the equity financing upon completion of an equity financing between \$3,500,000 and \$5,000,000; if no such equity financing is completed by November 15, 2017, then the loans shall become secured by a general security agreement over all assets of the Company; and, upon a change in control would either be payable on demand or convertible at the lesser of a price per share equal to that received by the parties in the change in control transaction or the market price of the shares. These conversion features were analyzed and determined to be contingent conversion features, accordingly, until the triggering event no beneficial conversion feature is recognized.

On August 14, 2017, the Company entered into an amendment to these convertible loans, whereby the interest was changed to a fixed rate of 12% per year from April 1, 2017 to August 14, 2017, and 3% per month from August 14, 2017 to maturity, which was extended to the earlier of March 31, 2018 or consummation of a qualified financing. The conversion feature was modified to contain the following terms: upon the consummation of an equity or equity-linked round of with an aggregate gross proceeds of \$7,000,000, without any action on part of the Holder, the outstanding principal, accrued and unpaid interest and premium amount equal to (25%) of the principal amount less the accrued and unpaid interest, will be converted into shares of new round stock based upon the lesser of (a) the lowest issuance (or conversion) price of new round stock in case there is more than one tranche of new round stock or (b) (\$0.25).

Further, the Company issued warrants to these debt holders amounting to 20% of the aggregate principal of the convertible loans divided by the exercise price, which would be determined as the lowest of a new round stock in a qualified financing, the average volume weighted average price for the sixty trading days prior to January 31, 2018 or \$0.25. The warrants have a term of five years.



**BIONIK LABORATORIES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**For the three and nine month periods ended December 31, 2017 and 2016 (unaudited)**

(Amounts expressed in U.S. Dollars)

**8. NOTES PAYABLE (Continued)**

An additional \$2,999,975 was received from these shareholders during the nine months ended December 31, 2017 for a total of \$4,999,975. For the three months and nine months ended December 31, 2017, an additional \$381,429 and \$587,699 of interest was accrued and expensed on these convertible loans.

The Company has recognized a discount against the convertible loans for the relative fair value of the warrants and is accreting the discount using the effective interest rate method. The assumptions used in valuing the warrants using the binomial valuation model were as follows: exercise price of \$0.25, volatility of 114%, risk-free interest rate of 1.91% and a term of five years.

The Company evaluated the fair value of the warrants attached to the convertible notes as \$548,178 and recorded \$290,375 of warrant accretion expense in the nine month period ended December 31, 2017.

<b>Balance, March 31, 2017</b>	2,017,488
Additional principal investment	2,999,975
Fair value of warrants	(548,178)
Accretion expense	290,375
Accrued Interest	587,699
<b>Balance, December 31, 2017</b>	<b><u>\$ 5,347,359</u></b>

(e) In May 2017, the Company's Chinese joint venture partners loaned the Company \$500,000 at an interest rate of 8% convertible into the Company's common shares upon a capital raise ("Qualified Financing") where gross proceeds exceed \$3,000,000 at the lesser of \$0.50 and the quotient of the outstanding balance on the conversion date by the price of the Qualified Financing. Additionally, the holders are entitled to warrants equaling 25% of the number of conversion shares to be issued at conversion. During the three and nine months ended December 31, 2017, \$10,082 and \$23,693 of interest was accrued and expensed on these convertible loans.

<b>Balance, March 31, 2017</b>	-
Additional principal investment	500,000
Accrued Interest	23,693
<b>Balance, December 31, 2017</b>	<b><u>\$ 523,693</u></b>

(f) In December 2017, investors of the Company advanced funds under a new convertible loan offering. These convertible loans bear interest at a fixed rate of 3% per month until the earlier of (a) January 31, 2018 and (b) the consummation of a qualified financing defined as gross proceeds of no less than \$7,000,000 and up to \$14,000,000 raised in one or more tranches. On the maturity date, without any action on the part of the Holder, the outstanding principal and accrued and unpaid interest under the notes will be converted into shares of new round stock based upon a (15%) discount to the lesser of (i) (A) the VWAP average of the last 30 days ending on the closing of the qualified financing (or, in the event of multiple closings, the lowest VWAP average of the last 30 days ending on each closing of a qualified financing) in the event of a maturity date referred to in clause (b) of the definition thereof, or (B) the VWAP average of the last 30 days before the maturity date in the event of a maturity date referred to in clause (a) of the definition thereof, and (ii) (\$0.18).

\$1,200,000 was received from these investors during the nine months ended December 31, 2017 and \$8,800 of interest was accrued and expensed on these convertible loans for the three months and nine months ended December 31, 2017.

<b>Balance, March 31, 2017</b>	-
Additional principal investment	1,200,000
Accrued Interest	8,800
<b>Balance, December 31, 2017</b>	<b><u>\$ 1,208,800</u></b>

**9. RELATED PARTY TRANSACTIONS AND BALANCES**

**a) Due from related parties**

As of December 31, 2017, there was an outstanding loan to the Chief Technology Officer and director of the Company for \$19,374 (March 31, 2017 - \$18,731). The loan has an interest rate of 1% based on the Canada Revenue Agency's prescribed rate for such advances and is denominated in Canadian dollars. During the nine months ended December 31, 2017, the Company accrued interest receivable in the amount of (\$649) (March 31, 2017 - \$707). The remaining fluctuation in the balance from the prior year is due to changes in foreign exchange.

**b) Accounts payable and accrued liabilities**

As at December 31, 2017, \$89,141 (March 31, 2017 - \$Nil) was owing to the CEO of the Company; \$47,307 (March 31, 2017 - \$Nil) to the former CTO) was owing to the Chief Technology Officer; \$16,592 (March 31, 2017 - \$Nil) was owing to the Chief Financial Officer, \$97,500 (March 31, 2017 - \$97,500) was owing to the Chief Commercialization Officer, and \$639,375 (March 31, 2017 - \$4,135) was

owing to the former CEO and current Chairman of the Board, all related to business, compensation and severance expenses, all of which are included in accounts payable or accrued liabilities.

**BIONIK LABORATORIES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**For the three and nine month periods ended December 31, 2017 and 2016 (unaudited)**

(Amounts expressed in U.S. Dollars)

**9. RELATED PARTY TRANSACTIONS AND BALANCES (Continued)**

In connection with the acquisition of IMT, the Company acquired a license agreement dated June 8, 2009, pursuant to which the Company pays the licensors an aggregate royalty of 1% of sales based on patent #8,613,6391. No sales were made, as the technology under this patent has not been commercialized. One of the licensors is a founder of IMT and a former officer and director of the Company.

As at the effective date of the merger pursuant to the Merger Agreement, a former officer and director received an aggregate of 5,190,376 shares of the Company in return for his ownership of IMT securities, in addition to his IMT options which were as of the effective date of the merger exercisable for an aggregate of 360,231 shares of common stock of the Company.

**10. SHARE CAPITAL**

	December 31, 2017		March 31, 2017	
	Number of shares	\$	Number of shares	\$
<b>Exchangeable Shares:</b>				
Balance beginning of period/year	47,909,336	47,910	50,000,000	50,000
Converted into common shares	(2,000,000)	(2,000)	(2,090,664)	(2,090)
Balance at the end of period/year	45,909,336	45,910	47,909,336	47,910
<b>Common Shares</b>				
Balance at beginning of the period	48,885,107	48,884	22,591,292	22,591
Shares issued on acquisition (Note 3)	-	-	23,650,000	23,650
Shares issued to exchangeable shares	2,000,000	2,000	2,090,664	2,090
Shares issued for services	-	-	217,047	217
Options exercised	-	-	110,096	110
Warrants exercise (a)	5,000,172	5,000	174,759	175
Cashless exercise of warrants	-	-	51,249	51
Balance at end of the period	55,885,279	55,884	48,885,107	48,884
<b>TOTAL COMMON SHARES</b>	101,794,615	101,794	96,794,443	96,794

- (a) During the nine month period ended December 31, 2017, the Company consummated an offer to amend and exercise to its warrant holders, enabling them to exercise their outstanding warrants for \$0.25 per share, and as a result, 5,000,172 common shares were issued for net proceeds of \$1,125,038 (Note 12).
- (b) During the nine month period ended December 31, 2016, 51,249 common shares were issued as a result of a cashless exercise of 262,045 warrants with an exercise price of \$0.80. Under the terms of the warrant agreement the value of the warrants on exercise is attributed to the shares on exercise and the Company has recognized a value of \$43,562.
- (c) The Company has a commitment to issue 250,000 common shares to a consultant during the nine months ended December 31, 2017 and recognized \$60,000 as compensation expense in general and administrative investor related services. The Company issued 70,000 common shares during the nine months period ended December 31, 2016 for consulting services and recognized \$59,500 of share compensation expense.

**Special Voting Preferred Share**

In connection with the Merger (Note 1), on February 26, 2015, the Company entered into a voting and exchange trust agreement (the "Trust Agreement"). Pursuant to the Trust Agreement, the Company issued one share of the Special Voting Preferred Stock, par value \$0.001 per share, of the Company (the Special Voting Preferred Share") to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Preferred Share for the benefit of the holders of the Exchangeable Shares (the "Beneficiaries"). Pursuant to the Trust Agreement, the Beneficiaries have voting rights in the Company equivalent to what they would have had, had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries.

In connection with the Merger and the Trust Agreement, effective February 20, 2015, the Company filed a certificate of designation of the Special Voting Preferred Share (the "Special Voting Certificate of Designation") with the Delaware Secretary of State. Pursuant to the Special Voting Certificate of Designation, one share of the Company's blank check preferred stock was designated as the Special Voting Preferred Share. The Special Voting Preferred Share entitles the Trustee to exercise the number of votes equal to the number of exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement.

The Special Voting Preferred Share is not entitled to receive any dividends or to receive any assets of the Company upon liquidation, and is not convertible into common shares of the Company.

The voting rights of the Special Voting Preferred Share will terminate pursuant to and in accordance with the Trust Agreement. The Special

Voting Preferred Share will be automatically cancelled at such time as no Exchangeable Shares are held by a Beneficiary.

**BIONIK LABORATORIES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**For the three and nine month periods ended December 31, 2017 and 2016 (unaudited)**

**(Amounts expressed in U.S. Dollars)**

**11. STOCK OPTIONS**

The purpose of the Company's equity incentive plan, is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company.

Options or other securities may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all options or other securities granted under the Plan shall not exceed 15% of the shares of common stock and Exchangeable Shares issued and outstanding (determined as of January 1 of each year). Optioned shares in respect of which options are not exercised shall be available for subsequent options.

On November 24, 2015, the Company granted 650,000 options granted to employees that vest over three years at the anniversary date. The grant date fair value of the options was \$694,384. During the year ended March 31, 2016, 250,000 options were cancelled and in the three and nine months ended December 31, 2017, \$35,609 and \$106,828 in share compensation expense was recognized.

On December 14, 2015, the Company granted 2,495,000 options to employees, directors and consultants that vest over three years at the anniversary date. The grant date fair value of the options was \$1,260,437. During the years ended March 31, 2016 and 2017, 25,000 options and 40,000 options, respectively, were cancelled, and in the first nine months ended December 31, 2017, 351,667 options were cancelled. On September 1, 2017, 666,667 options that were to vest equally December 14, 2017 and 2018 immediately vested. In the three and nine months ended December 31, 2017 \$45,396 and \$450,690 in compensation was recognized.

On April 21, 2016, the Company granted 3,000,000 stock options to employees of Bionik, Inc., the Company's wholly-owned subsidiary (formerly IMT) in exchange for 3,895,000 options that existed before the Company purchased IMT of which 1,000,000 have an exercise price of \$0.25, 1,000,000 have an exercise price of \$0.95 and 1,000,000 have an exercise price of \$1.05. The grant date fair value of vested options was \$2,582,890 and has been recorded as part of the acquisition equation (Note 3). For options that have not yet vested, share compensation expense in the first three months and the nine months ended December 31, 2017 was \$10,169 and \$30,508 was recognized.

On April 26, 2016, the Company granted 250,000 options to an employee with an exercise price of \$1.00 that vests over three years at the anniversary date. The grant date fair value was \$213,750. During the three and nine months ended December 31, 2017, \$17,813 and \$53,438 was recognized as share compensation expense.

On August 8, 2016, the Company granted 750,000 options to an employee with an exercise price of \$1.00 that vests over three years at the anniversary date. The grant date fair value was \$652,068. During the three months and nine months ended December 31, 2017 \$54,339 and \$163,017 of share compensation expense was recognized.

On February 6, 2017, the Company granted 400,000 options to an employee with an exercise price of \$0.70 that vests over three years at the anniversary date. The grant date fair value was \$245,200. Share compensation expense was recognized for the three and nine months ended December 31, 2017 of \$20,433 and \$61,300 was recognized.

On February 13, 2017, the Company granted 250,000 options to a consultant with an exercise price of \$0.68 that vests over one and one-half years, every six months. The grant date fair value was \$148,750. During the three months and nine months ended December 31 2017, \$12,390 and \$37,188 of share compensation expense was recognized.



**BIONIK LABORATORIES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**For the three and nine month periods ended December 31, 2017 and 2016 (unaudited)**

(Amounts expressed in U.S. Dollars)

**11. STOCK OPTIONS (Continued)**

On August 3, 2017, 1,500,000 options at \$0.21 to an executive officer, which vest equally over three future years. In addition, this executive officer was also granted up to 500,000 additional performance options based on meeting sales targets for the years ending March 31, 2018 and 2019. The performance options will vest at market price if the performance objectives are met. This grant had a grant date fair value of \$387,209 and a share compensation expense of \$22,639 and \$37,370 was recognized for the three and nine months ended December 31, 2017. These options were valued using the Black-Scholes model and the following inputs: expected life of 7 years, expected volatility 114% and a risk-free rate of 1.73%.

On September 1, 2017, the Company granted 12,215,354 options at \$0.161 equally to an executive officer and a consultant. 2,035,892 options have vested and 50% of the remaining options vest on performance being met and 50% vest annually over 5 years. The grant date fair value was \$1,832,304 and \$38,173 and \$343,919 is the current expenses for the three and nine months ended December 31, 2017. These options were valued using the Black-Scholes model and the following inputs: expected life of 10 years, expected volatility 114% and a risk-free rate of 1.91%.

During the three and nine months ended December 31, 2017, the Company recorded \$271,001 and \$1,284,257 in share-based compensation related to the vesting of stock options (December 31, 2016 - \$227,540 and \$592,130).

The following is a summary of stock options outstanding and exercisable as of December 31, 2017:

Exercise Price (\$)	Number of Options	Expiry Date	Exercisable Options
0.165	264,230	April 1, 2021	264,230
0.23	97,514	June 20, 2021	97,514
0.23	1,981,728	July 1, 2021	1,981,728
0.23	204,471	February 17, 2022	204,471
1.22	400,000	November 24, 2022	266,667
1.00	2,078,333	December 14, 2022	1,803,333
0.95	111,937	March 28, 2023	111,937
1.05	433,027	March 28, 2023	433,027
1.00	250,000	April 26, 2023	83,333
1.00	750,000	August 8, 2023	250,000
0.70	400,000	February 6, 2024	-
0.68	250,000	February 13, 2024	166,667
0.95	31,620	March 3, 2024	31,620
1.05	122,324	March 3, 2024	122,324
0.95	15,810	March 14, 2024	15,810
1.05	61,162	March 14, 2024	61,162
0.95	82,213	September 30, 2024	82,213
1.05	318,042	September 30, 2024	318,042
0.95	7,431	June 2, 2025	7,431
1.05	28,747	June 2, 2025	28,747
0.25	906,077	July 28, 2025	906,077
0.95	671,859	July 29, 2025	671,859
0.25	66,298	December 30, 2025	49,160
0.95	49,160	December 30, 2025	27,261
0.21	2,000,000	August 3, 2024	-
0.161	12,215,354	September 1, 2027	2,035,892
	<u>23,797,337</u>		<u>10,025,505</u>

The weighted-average remaining contractual term of the outstanding options was 7.76 (March 31, 2017 – 5.12) and for the options that are exercisable the weighted average was 6.23 (March 31, 2017 – 6.02)

**BIONIK LABORATORIES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**For the three and nine month periods ended December 31, 2017 and 2016 (unaudited)**

(Amounts expressed in U.S. Dollars)

**12. WARRANTS**

The following is a continuity schedule of the Company's common share purchase warrants:

	Number of Warrants	Weighted- Average Exercise Price (\$)
Outstanding and exercisable, March 31, 2015	10,823,450	1.35
Issued	7,225,625	1.35
Exercised	(148,787)	(0.80)
Outstanding and exercisable, March 31, 2016	17,900,288	1.35
Exercised	(262,045)	(0.80)
Outstanding and exercisable, March 31, 2017	17,638,243	1.35
Exercised	(5,000,172)	0.25
Dilution warrants issued to \$0.80 warrant holders	83,752	0.749
Dilution warrants issued to \$1.40 warrant holders	941,191	1.2933
Outstanding at December 31, 2017	13,663,014	1.241

During the nine month period ended December 31, 2017, the Company consummated an offer to amend and exercise its then outstanding warrants, enabling the holders of the warrants to exercise such warrants for \$0.25 per share. The Company received net proceeds of \$1,125,038. In addition due to an anti-dilution clause in the warrant agreements for such outstanding warrants an additional 83,752 warrants were issued to the \$0.80 warrant holders and 941,191 warrants were issued to the \$1.40 warrant holders. Furthermore, as a result of the anti-dilution clause, the exercise price of the warrants changed from \$0.80 to \$0.749 and from \$1.40 to \$1.2933 as a result of this transaction. The Company measured the effects of the triggered anti-dilution clause using the binomial tree model and recorded a loss of \$41,025 against retained earnings.

The Company issued 400,014 warrants exercisable at \$0.25 for four years expiring June 27, 2020 to the firm who facilitated the warrant offer.

During the year ended March 31, 2017 a warrant holder exercised 262,045 warrants on a cashless basis based on the terms of the warrant agreement and received 51,249 shares of common stock.

During the year ended March 31, 2016, a warrant holder exercised 148,787 warrants on a cashless basis based on the terms of the warrant agreement and was issued 45,508 shares of common stock.

**Common share purchase warrants**

The following is a summary of common share purchase warrants outstanding after the warrant offer to amend and exercise the additional warrant issue and the re-pricing of the warrants as of December 31, 2017:

Exercise Price (\$)	Number of Warrants	Expiry Date
1.2933	5,873,289	February 26, 2019
1.2933	1,229,040	March 27, 2019
1.2933	328,166	March 31, 2019
1.2933	2,544,240	April 21, 2019
1.2933	1,201,164	May 27, 2019
1.2933	1,173,370	June 30, 2019
0.7490	1,313,745	February 26, 2019
	13,663,014	

The weighted-average remaining contractual term of the outstanding warrants was 1.27 (March 31, 2017 – 1.77).

The exercise price and number of underlying shares with respect to the original \$0.80 and the \$1.40 warrants are expected to be further adjusted pursuant to the anti-dilution provisions therein, as a result of the issuance of the convertible promissory notes and warrants in 2016, 2017 and 2018. The anti-dilution provisions in these warrants are not able to be computed until the convertible promissory notes are converted, and the underlying shares can be determined in accordance with the terms thereunder.

**BIONIK LABORATORIES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**For the three and nine month periods ended December 31, 2017 and 2016 (unaudited)**

**(Amounts expressed in U.S. Dollars)**

**13. COMMITMENTS AND CONTINGENCIES**

**Contingencies**

From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors.

**Commitments**

On February 25, 2015, 262,904 common shares were issued to two former lenders connected with a \$241,185 loan received and repaid during fiscal 2013. The common shares were valued at \$210,323 based on the value of the concurrent private placement, and recorded in stock-based compensation on the consolidated statement of operations and comprehensive loss. As part of the consideration for the initial loan the former Chief Technology Officer and the new Chief Technology Officer had transferred 314,560 common shares to the lenders. For contributing the common shares to the lenders, the Company intends to reimburse the former Chief Technology Officer and the new Chief Technology Officer 320,000 common shares, each. As at December 31, 2017 and March 31, 2017, these shares have not yet been issued.

**14. RISK MANAGEMENT**

The Company's cash balances are maintained in two banks in Canada and a Canadian Bank subsidiary in the US. US Bank Deposits held in banks in Canada are insured up to \$100,000 CAD per depositor for each bank by The Canada Deposit Insurance Corporation, a federal crown corporation. Actual balances at times may exceed these limits.

**Interest Rate Risk**

Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. The Company has minimal exposure to fluctuations in the market interest rate. In seeking to minimize the risks from interest rate fluctuation the Company manages exposure through its normal operating and financing activities.

**Liquidity Risk**

Liquidity risk is the risk that the Company will incur difficulties meeting its financial obligations, as they are due. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due. Accounts payable and accrued liabilities are due within the current operating period. The Company has funded its operations through the issuance of capital stock, convertible debt and loans in addition to grants and investment tax credits received from the Government of Canada.

**15. SUBSEQUENT EVENTS**

(a) Subsequent to December 31, 2017, the Company received an additional \$606,400 from the lenders under the new terms of the loans described in note 8(f).

(b) Subsequent to December 31, 2017, the Company issued 3,640,000 options at \$0.155 to employees of the Company. The options will vest over three years - 1/3 on January 24, 2019, 1/3 on January 24, 2020 and 1/3 on January 24, 2021.

(c) Subsequent to December 31, 2017, the Company received a short term loan of \$500,000 due March 31, 2018 with interest of 1.5% per month from one of its directors.

## Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations

### Forward-looking Statements

This Quarterly Report on Form 10-Q contains statements reflecting assumptions, expectations, projections, intentions or beliefs about future events that are intended as “forward-looking statements”. All statements included or incorporated by reference in this Quarterly Report on Form 10-Q, other than statements of historical fact, that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements appear in a number of places, including, but not limited to in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements represent our reasonable judgment of the future based on various factors and using numerous assumptions and are subject to known and unknown risks, uncertainties and other factors that could cause our actual results and financial position to differ materially from those contemplated by the statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts, and use words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “may,” “will”, “should,” “plan,” “project” and other words of similar meaning. In particular, these include, but are not limited to, statements relating to the following:

- Projected operating or financial results, including anticipated cash flows used in operations;
- Expectations regarding capital expenditures; and
- Our beliefs and assumptions relating to our liquidity position, including our ability to obtain additional financing.

Any or all of our forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks, uncertainties and other factors including, among others:

- The loss of key management personnel on whom we depend;
- Our ability to operate our business efficiently, manage capital expenditures and costs (including general and administrative expenses) and obtain financing when required; and
- Our expectations with respect to our acquisition activity.

In addition, there may be other factors that could cause our actual results to be materially different from the results referenced in the forward-looking statements, some of which are included in this Quarterly Report on Form 10-Q, including in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Many of these factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our actual future results may vary materially from those expressed or implied in any forward-looking statements. All forward-looking statements contained in this Quarterly Report on Form 10-Q are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are made, and we disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q, except as otherwise required by applicable law.

This discussion and analysis should be read in conjunction with the accompanying condensed consolidated interim financial statements and related notes and the Company’s Annual Report on Form 10-K, for the year ended March 31, 2017 as filed with the Securities and Exchange Commission.

The discussion and analysis of the financial condition and results of operations are based upon the financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of any contingent liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. On an on-going basis we review our estimates and assumptions. The estimates were based on historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results are likely to differ from those estimates under different assumptions or conditions, but we do not believe such differences will materially affect our financial position or results of operations. Bionik, Inc.’s (IMT) operations are included since its acquisition on April 21, 2016 to December 31, 2017.

## Nature of Company

Bionik Laboratories Corp. is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility impair individuals, including three products in the market and four products in varying stages of development. The InMotion Systems - the InMotion ARM, In Motion Wrist, InMotion Hand – are designed to provide intelligent, adaptive therapy in a manner that has been clinically verified to maximize neuro-recovery. Bionik also has a lower-body exoskeleton under development - the ARKE - designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking. Bionik is developing with a partner, a lower body product based on some of the ARKE technology which should allow certain individuals with limited mobility to walk better. This product is expected to be launched in the consumer home market.

The Company acquired its in-market FDA listed products on April 21, 2016, when it acquired all of the outstanding shares and, accordingly, all assets and liabilities of IMT, a Boston, Massachusetts-based global pioneer and leader in providing effective robotic products for neurorehabilitation, pursuant to an Agreement and Plan of Merger, dated March 1, 2016, with IMT, Hermano Igo Krebs, and Bionik Mergerco Inc., a Massachusetts corporation and the Company's wholly owned subsidiary. The merger agreement provided for the merger of Bionik Mergerco with and into IMT, with IMT surviving the merger as its wholly-owned subsidiary. As consideration, IMT shareholders received an aggregate of 23,650,000 shares of the Company's common stock.

Through the acquisition of IMT, Bionik has added the portfolio focused on upper and lower extremity rehabilitation of stroke patients. Our product and development pipeline now includes three FDA listed upper extremity clinical rehabilitation products; a lower body product InMotion AnkleBot is being developed for clinical trials, as well as other potential new development product candidates. In addition, our development team has begun improvements to our current products that are on the market to be more competitive. We plan to develop other biomechanical solutions, including consumer-level medical assistive and rehabilitative products, through internal research and development and we may in the future further augment our product portfolio through technology acquisition opportunities.

The InMotion ARM, InMotion ARM/HAND, and InMotion Wrist have been characterized as Class II medical devices by the U.S. Food and Drug Administration ("FDA") and are listed with the FDA to market and sell in the United States. The products have also been sold in over 20 other countries. In addition to these in-market products, the InMotion AnkleBot is a development candidate, and we are also developing the InMotion Home, which is an upper extremity product that allows the patient to extend their therapy for as long as needed while rehabilitating at home. This is being developed on the same design platform as the InMotion clinical products. All of the above products are designed to provide intelligent, patient-adaptive therapy in a manner that has been clinically verified to maximize neuro-recovery.

Two hundred and fifty of our clinical robotics products for stroke have been sold in over 20 countries, including the United States. We have a growing body of clinical data for our products. In addition, our Massachusetts-base manufacturing facility is compliant with ISO-13485 and FDA regulations.

Bionik Laboratories Corp. was incorporated on January 8, 2010 in the State of Colorado. At the time of our incorporation the name of our company was Strategic Dental Management Corp. On July 16, 2013, we changed our name from Strategic Dental Management Corp. to Drywave Technologies, Inc. and changed our state of incorporation from Colorado to Delaware. Effective February 13, 2015, we filed with the Secretary of State of Delaware a Certificate of Amendment to our Articles of Incorporation whereby, among other things, we changed our name to Bionik Laboratories Corp.

## The Acquisition Transaction

On February 26, 2015, we entered into an Investment Agreement with Bionik Acquisition Inc. (the "Investment Agreement"), a company existing under the laws of Canada, and our wholly owned subsidiary ("Acquireco"), and Bionik Laboratories, Inc. ("Bionik Canada"), a company incorporated on March 24, 2011 under the Canada Business Corporations Act, whereby we acquired 100 Class 1 common shares of Bionik Canada representing 100% of the outstanding Class 1 common shares of Bionik Canada, taking into account the Exchangeable Share Transaction (as defined below) (the "Acquisition Transaction"). After giving effect to the Acquisition Transaction, we commenced operations through Bionik Canada.

Immediately prior to the closing of the Acquisition Transaction, we transferred all of the business, properties, assets, operations and goodwill of the Company (other than cash and cash equivalents), and liabilities as of March 6, 2013, to our then-existing wholly owned subsidiary, Strategic Dental Alliance, Inc., a Colorado corporation ("Strategic Dental Alliance"), and then transferred all of the capital stock of Strategic Dental Alliance to Brian E. Ray, a former officer and existing director (through March 20, 2015) and Jon Lundgreen, a former officer and director, pursuant to a Spin-Off Agreement (the "Spin-Off Agreement"). Also as of immediately prior to the closing of the Acquisition Transaction and the First Closing, we entered into an Assignment and Assumption Agreement with Tungsten 74 LLC, pursuant to which Tungsten 74 LLC assumed all of our remaining liabilities through the closing of the Acquisition Transaction (the "Assignment and Assumption Agreement"). Accordingly, as of the closing of the Acquisition Transaction and the First Closing, we had no assets or liabilities.

As a condition of the closing of the Acquisition Transaction, Bionik Canada created a new class of exchangeable shares (the "Exchangeable Shares"), which were issued to the existing common shareholders of Bionik Canada in exchange for all of their outstanding common shares, all of which were cancelled (the "Exchangeable Share Transaction").

Pursuant to the rights and privileges of the Exchangeable Shares, the holders of such Exchangeable Shares maintain the right to (i) receive dividends equal to, and paid concurrently with, dividends paid by the Company to the holders of Common Stock; (ii) vote, through the Trustee's voting of the Special Voting Preferred Stock (as defined herein) on all matters that the holders of Common Stock are entitled to vote upon; and (iii) receive shares of Common Stock upon the liquidation or insolvency of the Company upon the redemption of such Exchangeable Shares by Acquireco.

As part of the Exchangeable Share Transaction, we entered into the following agreements, each dated February 26, 2015:

- Voting and Exchange Trust Agreement (the "Trust Agreement") with Bionik Canada and Computershare Trust Company of Canada (the "Trustee"); and
- Support Agreement (the "Support Agreement") with Acquireco and Bionik Canada.

Pursuant to the terms of the Trust Agreement, the parties created a trust for the benefit of its beneficiaries, which are the holders of the Exchangeable Shares, enabling the Trustee to exercise the voting rights of such holders until such time as they choose to redeem their Exchangeable Shares for shares of the Common Stock of the Company, and allowing the Trustee to hold certain exchange rights in respect of the Exchangeable Shares.

As a condition of the Trust Agreement and prior to the execution thereof, we filed a Certificate of Designation with the Delaware Secretary of State, effective February 20, 2015, designating a class of our preferred shares as The Special Voting Preferred Stock (the "Special Voting Preferred Stock") and issued one share of the Special Voting Preferred Stock to the Trustee.

The Special Voting Preferred Stock entitles the Trustee to exercise the number of votes equal to the number of Exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement. The Trust Agreement further sets out the terms and conditions under which holders of the Exchangeable Shares are entitled to instruct the Trustee as to how to vote during any stockholder meetings of our company.

Pursuant to the terms of the Trust Agreement, we granted the Trustee the right to require our Company to purchase the Exchangeable Shares from any beneficiary upon the occurrence of certain events including in the event that we are bankrupt, insolvent or our business is wound up. The Trust Agreement continues to remain in force until the earliest of the following events: (i) no outstanding Exchangeable Shares are held by any beneficiary under the Trust Agreement; and (ii) each of Bionik Canada and us elects to terminate the Trust Agreement in writing and the termination is approved by the beneficiaries.

Pursuant to the terms of the Support Agreement, we agreed to certain covenants while the Exchangeable Shares were outstanding, including: (i) not to declare or pay any dividends on our common stock unless simultaneously declaring the equivalent dividend for the holders of the Exchangeable Shares, (ii) advising Bionik Canada in advance of any dividend declaration by our company, (iii) ensure that the record date for any dividend or other distribution declared on the shares of the Company is not less than seven days after the declaration date of such dividend or other distribution; (iv) taking all actions reasonably necessary to enable Bionik Canada to pay and otherwise perform its obligations with respect to the issued and outstanding Exchangeable Shares, (iv) to ensure that shares of the Company are delivered to holders of Exchangeable Shares upon exercise of certain redemption rights set out in the agreement and in the rights and restrictions of the Exchangeable Shares, and (v) reserving for issuance and keeping available from our authorized common stock such number of shares as may be equal to: (A) the number of Exchangeable Shares issued and outstanding from time to time; and (B) the number of Exchangeable Shares issuable upon the exercise of all rights to acquire Exchangeable Shares from time to time.

The Support Agreement also outlines certain restrictions on our ability to issue any dividends, rights, options or warrants to all or substantially all of our stockholders during the term of the agreement unless the economic equivalent is provided to the holders of Exchangeable Shares. The Support Agreement is governed by the laws of the Province of Ontario.

Between the closing of the Acquisition Transaction and June 30, 2015, we sold in a series of closing an aggregate of 16,408,250 units (the "Units") for gross proceeds of \$13,126,600 in a private placement offering (the "Offering"). Each Unit consisted of one share of common stock, par value \$0.001 per share (the "Common Stock") and a four year warrant (the "Warrant") to purchase one share of Common Stock at an initial exercise price of \$1.40 per share.

In addition, the placement agent in the Offering and its sub-agents were issued 10% warrant coverage for all Units sold in the Offering, exercisable at \$0.80 per share for a period of 4 years.

### **Significant Accounting Policies and Estimates**

The discussion and analysis of the financial condition and results of operations are based upon the condensed consolidated interim financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of any contingent liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. On an on-going basis we review our estimates and assumptions. The estimates were based on historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results are likely to differ from those estimates under different assumptions or conditions, but we do not believe such differences will materially affect our financial position or results of operations.

## Results of Operations

From the inception of Bionik Canada on March 24, 2011 through to December 31, 2017, we have generated a deficit of \$29,554,125.

We expect to incur additional operating losses during this quarter and through March 31, 2018 and beyond, principally as a result of our continuing research and development, building the sales and marketing team, long sales cycles and general and administrative costs predominantly associated with being a public company.

Our results of operations are presented for the three and nine months ended December 31, 2017 with comparatives for the three and nine months ended December 31, 2016.

### *Sales*

The Company recorded revenue of \$260,960 and \$570,327 for the three and nine months ended December 31, 2017 compared to \$372,426 and \$553,900 for the three and nine months ended December 31, 2016. The increase in the revenues results from our growing sales team starting to deliver on a significant pipeline of opportunities, which we hope will continue in the future.

### *Cost of sales*

The Company recorded cost of sales of \$88,357 and \$177,482 for the three and nine months ended December 31, 2017, compared to \$334,786 and \$405,680 for the three and nine months ended December 31, 2016. The decrease in cost of good sold results from lower unit sales as well as a \$43,009 inventory write-off in the period ended December 31, 2016.

### *Operating Expenses*

Total operating expenses for the three and nine months ended December 31, 2017 was \$2,347,916 and \$8,068,811 compared to \$1,609,954 and \$5,450,290 for the three and nine months ended December 31, 2016, as further detailed below.

Sales and marketing expenses for the three and nine months ended December 31, 2017 was \$432,260 and \$1,313,077 compared to the three and nine months ended December 31, 2016 of \$377,046 and \$646,509. The sales and marketing team was expanded starting in August 2016, and January through February 2017 with the addition of five sales and marketing employees, including a Chief Commercialization Officer and marketing and sales support to support the launch of the new InMotion V2 product in the fall of 2017. Prior years expenses included two sales employees and their expenses since the acquisition of IMT on April 21, 2016.

Research and development expenses for the three and nine months ended December 31, 2017 were \$546,350 and \$1,947,659 compared to the three and nine months ended December 31, 2016 of \$571,671 and \$1,803,234. The increase for the nine months ended December 31, 2017 compared to December 31, 2016, primarily relates to additional development and prototyping costs for our new product development projects.

For the three and nine months ended December 31, 2017, we incurred general and administrative expenses of \$783,784 and \$2,916,917, compared to general and administrative expenses of \$409,669 and \$2,291,136 for the three and nine months ended December 31, 2016. The increase in these expenses is primarily due to public company related expenses, the addition of a new employee and a consultant, increased compensation to our new CEO who started September 1, 2017 as well as the amounts owing to the former CEO of the Company. The expenses for the three and nine month period ended December 31, 2016 include the expenses related to the IMT acquisition in 2016. In addition, the previous year's costs included cost of our former Chief Operating Officer; this position was reallocated to research and development in the current fiscal year.

For the three and nine months ended December 31, 2017, the Company recorded \$271,001 and \$1,284,257 in share-based compensation expense compared to \$227,540 and \$651,630 for the three and nine months ended December 31, 2016, due to the increase in options issued in 2017 over 2016.

For the three and nine months ended December 31, 2017, the Company recorded \$216,302 and \$290,375 as warrant accretion expense compared to \$Nil for the three and nine months ended December 31, 2016 due to the amortization of the fair value of warrants related to the convertible notes.

### *Other Expenses*

For the three and nine months ended December 31, 2017, we incurred interest expenses of \$416,990 and \$657,350 compared to interest expenses of \$13,808 and \$23,839 for the three and nine months ended December 31, 2016. The increase in interest expense relates to the Company having more high interest bearing debt during the three and nine month period ended December 31, 2017 when compared to December 31, 2016.

Some of the Company's outstanding warrants include price protection provisions that allow for a reduction in the exercise price of the warrants in the event the Company subsequently issues common stock or options, rights, warrants or securities convertible or exchangeable for shares of common stock at a price lower than the exercise price of the outstanding warrants, subject to certain important exceptions. Simultaneously, due to an anti-dilution clause, the number of shares of common stock that may be purchased upon exercise of each of these outstanding warrants shall be increased based on a pre-defined formula.





The adaptation of the FASB issued, ASU No. 2017-11, *Earnings Per Share (Topic 260) Distinguishing Liabilities From Equity (Topic 480) Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments With Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instrument of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception*, allows a financial instrument with a down-round feature to no longer automatically be classified as a liability solely based on the existence of the down-round provision. The update means the instrument does not have to be accounted for as a derivative and be subject to an updated fair value measurement each reporting period. The Company has adopted ASU No.2017-11 in the quarter ended December 31, 2017.

#### *Other Income*

For the three and nine months ended December 31, 2017, we had other expense of \$59 and other income of \$649 compared to other income of \$4,363 and \$410,877 for the three and nine months ended December 31,2016. Prior year higher amounts are related to refundable scientific tax credits that the Company is no longer eligible for.

#### *Comprehensive Loss*

Comprehensive loss for the three and nine months ended December 31, 2017 amounted to \$(2,580,759) and \$(8,436,636) resulting in a loss per share of \$(0.03) and \$(0.08), compared to a loss of \$(1,581,759) and \$(4,915,032) for the three and nine months ended December 31, 2016, as adjusted resulting in a loss per share of \$(0.02) and loss per share of \$(0.05).

#### **Liquidity and Capital Resources**

We have funded operations through the issuance of capital stock, loans, grants and investment tax credits received from the Government of Canada. The Company raised in its 2015 private offering net proceeds of \$11,341,397. Since 2015, the Company also obtained funds through additional government tax credits, incurring new convertible indebtedness totaling \$6,699,975, short term loan of \$400,000 and raising \$1,125,038 in June 2017 from its warrant solicitation. At December 31, 2017, the Company had cash and cash equivalents of \$998,661.

Based on our current burn rate, we need to raise additional capital in the short term to fund operations and meet expected future liquidity requirements, or we will be required to curtail or terminate some or all of our product lines or our operations. We are seeking to raise up to \$14 million through a convertible notes offering, which, if successful, will enable us to continue operations based on our current burn rate, for the next 12 months. Further all of our convertible notes will automatically convert into equity if an upon the successful closing of at least \$7 million in such offering. We cannot give any assurance at this time that we will successfully raise all of such capital or any other capital. The Company expects a combination of the foregoing and any other successful financings, if any, to meet the Company's anticipated cash requirements for the next 12 months; however, these conditions raise substantial doubt about the Company's ability to continue as a going concern. The accompanying condensed consolidated interim financial statements do not include any adjustments to reflect the possible future effects on recoverability and reclassification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

Additionally, we will need additional funds to respond to business opportunities including potential acquisitions of complementary technologies, protect our intellectual property, develop new lines of business and enhance our operating infrastructure. While we may need to seek additional funding for any such purposes, we may not be able to obtain financing on acceptable terms, or at all. In addition, the terms of our financings may be dilutive to, or otherwise adversely affect, holders of our common stock. We will also seek additional funds through arrangements with collaborators or other third parties. We may not be able to negotiate any such arrangements on acceptable terms, if at all. If we are unable to obtain additional funding on a timely basis, we may be required to curtail or terminate some or all of our product lines or our operations.

#### *Net Cash Used in Operating Activities*

During the nine months ended December 31, 2017, we used cash in operating activities of \$(5,215,697) compared to \$(5,540,946) for the nine months ended December 31, 2016. The decreased use of cash is mainly attributable to decreased prepaid expenses and increased accounts payable liability in the nine months ended December 31, 2017 over the nine months ended December 31, 2016.

#### *Net Cash Used in Investing Activities*

During the nine months ended December 31, 2017, net cash used in investing activities was \$(17,182) (December 31, 2016 - (\$9,827)) related to equipment purchases.

#### *Net Cash Provided by Financing Activities*

Net cash provided by financing activities was \$5,687,890 for the nine months ended December 31, 2017 compared to net cash provided by financing activities of \$749,968 for the nine months ended December 31, 2016. The increase in the nine months ended December 31, 2017 is due to receipt of an additional \$4,699,975 as convertible loans, \$400,000 as a short term loan provided by a director of the Company and repaid in January 2018 and \$1,125,038 received from the Company's offer to amend and exercise its outstanding warrants which closed in June 2017, which resulted in 5,001,172 common shares being issued. The Company also paid back \$200,000 of principal and \$49,505 of interest to a promissory note holder and \$208,359 of principal and \$79,259 of interest to its demand loan holders.

## Recently Issued Accounting Pronouncements

In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)". The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. Early adoption is not permitted. The impact on the condensed consolidated interim financial statements of adopting ASU 2014-09 will be assessed by management.

In November 2015, the FASB issued ASU No. 2015-17, "Balance Sheet Classification of Deferred Taxes," which requires that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company does not anticipate that the adoption of ASU No. 2015-17 will have a material effect on the condensed consolidated interim financial position or the consolidated results of operations.

In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The update makes several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company is still assessing the impact that the adoption of AS 2016-01 will have on the condensed consolidated interim financial position and the consolidated results of operations.

In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the consolidated financial position and the consolidated results of operations.

In March 2016, the FASB issued ASU 2016-09, "Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting". Several aspects of the accounting for share-based payment award transaction are simplified, including (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The Company has adopted this policy during the period and there was no impact on the condensed consolidated interim financial statements.

In August 2016, the FASB issued ASU 2016-15, "Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments". This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company is still assessing the impact that the adoption of ASU 2016-15 will have on the consolidated statement of cash flows.

In January 2017, the FASB issued ASU 2017-01, "Business Combinations: Clarifying the definition of a Business" which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquired is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term "outputs" to be consistent with how it described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date.

In January 2017, the FASB issued ASU 2017-04, "Intangibles – Goodwill and Other" ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit's carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019.

In September 2017, the FASB issued ASU 2017-13, "Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842)". ASU 2017-13 amends the early adoption date option for certain companies related to the adoption of ASU 2014-09 and ASU 2016-02. The Company is not early adopting this standard; however, we are currently assessing the impact that the eventual adoption of this standard will have on the Company.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying condensed consolidated interim financial statements

## Off Balance Sheet Arrangements

We have no off-balance sheet transactions.

## Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable for smaller reporting companies.



#### **Item 4. Controls and Procedures**

During the nine months ended December 31, 2017, there were no changes in our internal controls over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We maintain “disclosure controls and procedures” as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

As of the end of the period covered by this Quarterly Report, we carried out an evaluation, under the supervision and with the participation of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rules 13a-15(b) and 15d-15(b). Based upon this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures as of the end of the period covered by this Quarterly Report were ineffective due to a lack of segregation of duties and as a result of a transition of duties with new management starting as of September 1, 2017.

### **PART II - OTHER INFORMATION**

#### **Item 1. Legal Proceedings**

None

#### **Item 1A. Risk Factors**

Not applicable for smaller reporting companies

#### **Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

All unregistered issuances of equity securities during the period covered by this quarterly report have been previously disclosed on our Current Reports on Form 8-K.

#### **Item 3. Defaults Upon Senior Securities.**

None

#### **Item 4. Mine Safety Disclosures**

Not applicable

#### **Item 5. Other Information**

None

#### **Item 6. Exhibits**

[Exhibit 10.1 – Form of Subscription](#)

[Exhibit 10.2 – Form of Convertible Promissory Note](#)

[Exhibit 31.1 - Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](#)

[Exhibit 31.2 - Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](#)

[Exhibit 32.1 - Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](#)

[Exhibit 32.2 - Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](#)

Exhibit 101.INS - XBRL Instance Document

Exhibit 101.SCH - XBRL Taxonomy Extension Schema Document

Exhibit 101.CAL - XBRL Taxonomy Extension Calculation Linkbase Document

Exhibit 101.DEF - XBRL Taxonomy Extension Definition Linkbase Document

Exhibit 101.LAB - XBRL Taxonomy Extension Label Linkbase Document

Exhibit 101.PRE - XBRL Taxonomy Extension Presentation Linkbase Document

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: February 13, 2018

BIONIK LABORATORIES CORP.

By: /s/ Eric Dusseux  
Name: Eric Dusseux  
Chief Executive Officer (Principal Executive Officer)

By: /s/ Leslie Markow  
Name: Leslie Markow  
Chief Financial Officer  
(Principal Financial and Accounting Officer)

**SUBSCRIPTION AGREEMENT**

This **Subscription Agreement** (this "**Agreement**") is made as of the date set forth on the signature page hereto, by and among **Bionik Laboratories Corp.**, a Delaware corporation (the "**Company**"), and the subscribers identified on the signature pages hereto (each, a "**Subscriber**" and collectively, the "**Subscribers**").

**Recitals**

**Whereas**, the Company seeks to sell up to US\$14,000,000 (the "**Total Amount**") in Convertible Promissory Notes in the form annexed hereto as **Exhibit A** (each, a "**Note**" and collectively, the "**Notes**") pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "**Securities Act**"), Rule 506(b) of Regulation D ("**Regulation D**") and/or Regulation S ("**Regulation S**") as promulgated under the Securities Act (the "**Offering**"); and

**Whereas**, the Subscribers wish to purchase Notes in the amount set forth on (the "**Subscription Amount**"), and in accordance with the lending percentages set forth opposite their respective names on (each, a "**Proportionate Percentage**"), their respective Signature Page to this Agreement.

**Now, Therefore**, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Subscribers hereby agree as follows:

**1. PURCHASE OF CONVERTIBLE PROMISSORY NOTES.**

**1 . 1 Subscription.** Subject to the terms and conditions herein, the Subscribers will loan to the Company such amounts, and the Company shall borrow from the Subscribers, in accordance with the Proportionate Percentage and at such dates as mutually agreed upon between the Company and the Subscribers (each such date, a "**Funding Date**").

**1 . 2 Payment for Subscription.** Each Subscriber agrees that the Subscription Amount to the Company for the amount of the Subscriber's Subscription is to be made upon the Initial Closing (as defined below) and on each additional Closing (as defined below), by check or by wire transfer to an account designated by the Company.

**1.3 Closing.**

( **a** ) The closing of the subscriptions for the Notes shall occur on each Funding Date (collectively, the "**Closings**" and each, without distinction, a "**Closing**"). Each Closing shall be held remotely by the electronic exchange of documents and funds at such time and by such means upon which the Company and the Subscribers purchasing the Notes at such Closing shall agree.

( **b** ) At each Closing, the Company shall deliver to the Subscribers executed Notes in the amounts determined for each Purchaser pursuant to this Section 1.

## 2. REPRESENTATIONS AND WARRANTIES.

**2.1 Representations and Warranties by the Company.** The Company represents and warrants to each Subscriber that:

(a) **Authorization.** The Company has all corporate right, power and authority to enter into this Agreement and to consummate the transactions contemplated hereby. All corporate action on the part of the Company, its directors and stockholders necessary for the: (i) authorization execution, delivery and performance of this Agreement by the Company; (ii) authorization, sale, issuance and delivery of the Notes contemplated hereby and the performance of the Company's obligations hereunder; and (iii) authorization, issuance and delivery of the securities issuable upon conversion of the Notes (other than the Company having to increase its authorized shares of common stock as contemplated in Section 3.2(a) of the Notes), has been taken. The securities issuable upon conversion of the Notes will be validly issued, fully paid and nonassessable.

(b) **Enforceability.** Assuming this Agreement has been duly and validly authorized, executed and delivered by the parties hereto and thereto other than the Company, this Agreement is duly authorized, executed and delivered by the Company constitutes the legal, valid and binding obligations of the Company enforceable against the Company in accordance with its terms, except as such enforcement is limited by general equitable principles, or by bankruptcy, insolvency and other similar laws affecting the enforcement of creditors rights generally.

(c) **No Violations.** The execution, delivery and performance of this Agreement and the Notes by the Company and the consummation by the Company of the transactions contemplated hereby and thereby will not (i) result in a violation of the Certificate of Incorporation of the Company or other organizational documents of the Company, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree applicable to the Company by which any property or asset of the Company is bound or affected.

**2.2 Disclaimer.** It is specifically understood and agreed by each Subscriber that the Company has not made, nor by this Agreement shall be construed to make, directly or indirectly, explicitly or by implication, any representation, warranty, projection, assumption, promise, covenant, opinion, recommendation or other statement of any kind or nature with respect to the anticipated profits or losses of the Company, except as otherwise provided with this Agreement.

**2 . 3 Representations and Warranties by the Subscribers.** Each Subscriber represents and warrants to the Company that:

( a ) The Subscriber is acquiring the Notes for the Subscriber's own account, as principal, for investment purposes only and not with any intention to resell, distributes or otherwise dispose of the Notes, in whole or in part.

(b) The Subscriber has had an unrestricted opportunity to: (i) obtain information concerning the Offering, including the Notes, the Company and its proposed and existing business and assets; and (ii) ask questions of, and receive answers from the Company concerning the terms and conditions of the Offering and to obtain such additional information as may have been necessary to verify the accuracy of the information contained in the this Agreement or otherwise provided.

(c) The Subscriber has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of investing in the Company, and all information that the Subscriber has provided concerning the Subscriber, the Subscriber's financial position and knowledge of financial and business matters is true, correct and complete.

(d) The Subscriber has relied solely on the advice of, or has consulted with, in regard to the legal, investment and tax considerations involved in the purchase, ownership and disposition of Notes, the Subscriber's own legal counsel, business and/or investment adviser, accountant and tax adviser.

(e) If the Subscriber is an entity, the Subscriber is duly organized, validly existing and in good standing under the laws of its jurisdiction of incorporation or organization, as the case may be. The Subscriber has all requisite power and authority to own its properties, to carry on its business as presently conducted, to enter into and perform this Agreement, the Notes and the agreements, documents and instruments executed, delivered and/or contemplated hereby (collectively, the "**Subscription Documents**") to which it is a party and to carry out the transactions contemplated hereby and thereby. The Subscription Documents are valid and binding obligations of the Subscriber, enforceable against it in accordance with their terms, except as enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar laws, from time to time in effect, which affect enforcement of creditors' rights generally. If applicable, the execution, delivery and performance of the Subscription Documents to which it is a party have been duly authorized by all necessary action of the Subscriber. The execution, delivery and performance of the Subscription Documents and the performance of any transactions contemplated by the Subscription Documents will not: (i) violate, conflict with or result in a default (whether after the giving of notice, lapse of time or both) under any contract or obligation to which the Subscriber is a party or by which it or its assets are bound, or any provision of its organizational documents (if an entity), or cause the creation of any lien or encumbrance upon any of the assets of the Subscriber; (ii) violate, conflict with or result in a default (whether after the giving of notice, lapse of time or both) under, any provision of any law, regulation or rule, or any order of, or any restriction imposed by any court or other governmental agency applicable to the Subscriber; (iii) require from the Subscriber any notice to, declaration or filing with, or consent or approval of any governmental authority or other third party other than pursuant to federal or state securities or blue sky laws; or (iv) accelerate any obligation under, or give rise to a right of termination of, any agreement, permit, license or authorization to which the Subscriber is a party or by which it is bound.

(f) At the time the Subscriber was offered the Notes, it was, and at the date hereof it is, and on each Funding Date and date on which the Subscriber converts the Notes the Subscriber will be, an "accredited investor" as defined in Rule 501(a) under the Securities Act. The Subscriber hereby represents that neither the Subscriber nor any of its Rule 506(d) Related Parties is a "bad actor" within the meaning of Rule 506(d) promulgated under the Securities Act. For purposes of this Agreement, "**Rule 506(d) Related Party**" shall mean a person or entity covered by the "Bad Actor disqualification" provision of Rule 506(d) of the Securities Act.



### 3. MISCELLANEOUS.

**3.1 Addresses and Notices.** All notices, demands, consents, requests, instructions and other communications to be given or delivered or permitted under or by reason of the provisions of this Agreement or in connection with the transactions contemplated hereby shall be in writing and shall be deemed to be delivered and received by the intended recipient as follows: (i) if personally delivered, on the business day of such delivery (as evidenced by the receipt of the personal delivery service); (ii) if mailed certified or registered mail return receipt requested, two (2) business days after being mailed; or (iii) if delivered by overnight courier (with all charges having been prepaid), on the business day of such delivery (as evidenced by the receipt of the overnight courier service of recognized standing). If any notice, demand, consent, request, instruction or other communication cannot be delivered because of a changed address of which no notice was given (in accordance with this Section 3.1, or the refusal to accept same, the notice, demand, consent, request, instruction or other communication shall be deemed received on the second business day the notice is sent (as evidenced by a sworn affidavit of the sender). All such notices, demands, consents, requests, instructions and other communications will be sent to the following addresses or facsimile numbers as applicable:

If to the Company to:                    Bionik Laboratories Corp.  
483 Bay Street, N105  
Toronto, ON M5G 2C9  
Attention: CEO

With copies to:                         Ruskin Moscou Faltischek, PC  
1425 RXR Plaza  
East Tower, 15<sup>th</sup> Floor  
Uniondale, New York 11556  
Attention: Stephen E. Fox, Esq.

If to the Subscriber, to the address set forth on the signature page annexed hereto.

Any such person may by notice given in accordance with this Section 3.1 to the other parties hereto designate another address or person for receipt by such person of notices hereunder.

**3.2 Titles and Captions.** All Article and Section titles or captions in this Agreement are for convenience only. They shall not be deemed part of this Agreement and do not in any way define, limit, extend or describe the scope or intent of any provisions hereof.

**3.3 Assignability.** This Agreement is not transferable or assignable by the undersigned.

**3 . 4 Pronouns and Plurals.** Whenever the context may require, any pronoun used herein shall include the corresponding masculine, feminine or neuter forms. The singular form of nouns, pronouns and verbs shall include the plural and vice versa.

**3.5 Further Action.** The parties shall execute and deliver all documents, provide all information and take or forbear from taking all such action as may be necessary or appropriate to achieve the purposes of this Agreement. Each party shall bear its own expenses in connection therewith.

**3.6 Applicable Law.** This Agreement shall be construed in accordance with and governed by the laws of the State of Delaware without regard to its conflict of law rules.

**3 . 7 Binding Effect.** This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, administrators, successors, legal representatives, personal representatives, permitted transferees and permitted assigns. If the undersigned is more than one person, the obligation of the undersigned shall be joint and several and the agreements, representations, warranties and acknowledgments herein contained shall be deemed to be made by and be binding upon each such person and such person's heirs, executors, administrators and successors.

**3 . 8 Integration.** This Agreement, together with the remainder of the Subscription Documents of which this Agreement forms a part, constitutes the entire agreement among the parties pertaining to the subject matter hereof and supersedes and replaces all prior and contemporaneous agreements and understandings, whether written or oral, pertaining thereto. No covenant, representation or condition not expressed in this Agreement shall affect or be deemed to interpret, change or restrict the express provisions hereof.

**3.9 Amendment.** This Agreement and the Notes may be amended only with the written consent of the Company and the holders of a majority of the aggregate principal amount of the Notes (a "**Majority in Interest**"). The conditions or observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only by written instrument and with respect to conditions or performance obligations benefiting the Company, by the Company, and with respect to conditions or performance obligations benefiting the Subscribers, only with the consent of a Majority in Interest. Any amendment or waiver effected in accordance with this Section 3.9 shall be binding on all holders of the Notes, even if they do not execute such amendment, consent or waiver, as the case may be.

**3.10 Creditors.** None of the provisions of this Agreement shall be for the benefit of or enforceable by creditors of any party.

**3 . 1 1 Waiver.** No failure by any party to insist upon the strict performance of any covenant, agreement, term or condition of this Agreement or to exercise any right or remedy available upon a breach thereof shall constitute a waiver of any such breach or of such or any other covenant, agreement, term or condition.

**3.12 Rights and Remedies.** The rights and remedies of each of the parties hereunder shall be mutually exclusive, and the implementation of one or more of the provisions of this Agreement shall not preclude the implementation of any other provision.

**3.13 Counterparts.** This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy of this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a ".pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or ".pdf" signature page were an original thereof.

**signatures on the following pages**

**In Witness Whereof**, the undersigned has executed this Agreement on this \_\_\_\_ day of \_\_\_\_\_, 2017.

Signature of Subscriber:

By: \_\_\_\_\_  
Name: \_\_\_\_\_ Print Name of Subscriber  
Title: \_\_\_\_\_

\_\_\_\_\_  
Social Security Number(s) or EIN

Mailing Address of Subscriber(s)	Residence of Subscriber(s)
_____ Street	_____ Street
_____ City State Zip Code	_____ City State Zip Code

If Joint Ownership, check one:

- Joint Tenants with Right of Survivorship
- Tenants-in-Common
- Tenants by the Entirety
- Community Property
- Other (specify): \_\_\_\_\_

Proportionate Percentage: \_\_\_\_\_ %

\$ \_\_\_\_\_  
Aggregate Subscription Amount

Method of Payment:  Wire Transfer  Check

FOREGOING SUBSCRIPTION ACCEPTED:

**Bionik Laboratories Corp.**

By: \_\_\_\_\_  
Name: Eric Dusseux  
Title: CEO

**Signature Page to Subscription Agreement**

\_\_\_\_\_

**Exhibit A**

**CONVERTIBLE PROMISSORY NOTE**

[See attached]

---

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS.

---

**BIONIK LABORATORIES CORP.**

**CONVERTIBLE PROMISSORY NOTE**

**Principal Amount:** US\$[\_\_\_\_\_]

**Issue Date:** [\_\_\_\_\_]

**Bionik Laboratories Corp.**, a Delaware corporation (the “*Company*”), for value received, hereby promises to pay to [\_\_\_\_\_] or his permitted assigns or successors (the “*Holder*”), the principal amount of [\_\_\_\_\_] Dollars (US\$[\_\_\_\_]) (the “*Principal Amount*”), without demand, on the Maturity Date (as hereinafter defined), together with any accrued and unpaid interest due thereon. This Note shall bear interest at a fixed rate of 3% per month, beginning on the Issue Date. Interest shall be computed based on a 360-day year of twelve 30-day months and shall be payable, along with the Principal Amount, on the Maturity Date. Except as set forth in Section 3.1, payment of all principal and interest due shall be in such coin or currency of the United States of America as shall be legal tender for the payment of public and private debts at the time of payment.

This Note is a convertible promissory note referred to in that certain Subscription Agreement dated as of the date hereof, or series of like subscription agreements (the “*Subscription Agreement*”), among the Company and the subscribers named therein, pursuant to which the Company is seeking to borrow up to \$14,000,000 (the “*Offering*”).

**1. DEFINITIONS.**

**1.1 Definitions.** The terms defined in this Section 1 whenever used in this Note shall have the respective meanings hereinafter specified.

“*Change in Control*” means a merger or consolidation of the Company with or into any other entity in which the stockholders of the Company immediately prior to the merger or consolidation do not own more than 50% of the outstanding voting power (assuming conversion of all convertible securities and the exercise of all outstanding options and warrants) of the surviving entity or the sale, lease, licensing, transfer or other disposition of all or substantially all the assets of the Company; provided, however, that any new issuance of capital stock (or securities convertible or exercisable into capital stock) of the Company to one or more third parties for the sole purpose of providing funding for the Company shall not constitute a Change in Control.

“*Common Stock*” means the common stock, par value \$0.001 per share, of the Company.

**“Conversion Shares”** means the New Round Stock issued or issuable to the Holder pursuant to Article 3.

**“Event of Default”** shall have the meaning set forth in Section 6.1.

**“Holder”** or **“Holders”** means the person named above or any Person who shall thereafter become a recordholder of this Note in accordance with the terms hereof.

**“Issue Date”** means the issue date stated above.

**“Maturity Date”** shall mean the earlier of: (a) January 31, 2018 and (b) the consummation of a Qualified Financing.

**“New Round Stock”** means Common Stock.

**“Note”** means this Convertible Note, as amended, modified or restated.

**“Person”** means an individual, corporation, partnership, limited liability company, association, trust, joint venture, unincorporated organization or any government, governmental department or agency or political subdivision thereof.

**“Qualified Financing”** means the Offering, provided the Company raises in one or more tranches aggregate gross proceeds of no less than \$7,000,000 and up to \$14,000,000 pursuant to the Subscription Agreement.

**“Securities Act”** means the United States Securities Act of 1933, as amended.

**“Trading Market”** means the OTCQX market place of the OTC Markets; provided however, that in the event the Company’s Common Stock is ever listed or traded on the New York Stock Exchange, the NYSE Amex Equities, the Nasdaq Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market, or the OTCQB market place of the OTC Markets, then the “Trading Market” shall mean such other market or exchange on which the Company’s Common Stock is then listed or traded.

**“VWAP”** means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a trading day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed or quoted for trading on a Trading Market and if prices for the Common Stock are then reported on the OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (c) in all other cases, the fair market value of a share of Common Stock as determined by the Board of Directors of the Company in good faith.

## 2. GENERAL PROVISIONS.

**2.1 Loss, Theft, Destruction of Note.** Upon receipt of evidence satisfactory to the Company of the loss, theft, destruction or mutilation of this Note and, in the case of any such loss, theft or destruction, upon receipt of indemnity or security reasonably satisfactory to the Company, or, in the case of any such mutilation, upon surrender and cancellation of this Note, the Company will make and deliver, in lieu of such lost, stolen, destroyed or mutilated Note, a new Note of like tenor and unpaid principal amount dated as of the date hereof. This Note shall be held and owned upon the express condition that the provisions of this Section 2.1 are exclusive with respect to the replacement of a mutilated, destroyed, lost or stolen Note and shall preclude any and all other rights and remedies notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to the replacement of negotiable instruments or other securities without their surrender.

**2.2 Prepayment; Redemption.** This Note may not be prepaid by the Company in whole or in part, except with the prior written consent of the Holder. This Note may not be redeemed by the Company in whole or in part, except with the prior written consent of the Holder.

## 3. CONVERSION OF NOTE.

### 3.1 Conversion.

**(a) Conversion upon Maturity Date.** On the Maturity Date without any action on the part of the Holder, the outstanding principal and accrued and unpaid interest under the Notes will be converted into shares of New Round Stock based upon a fifteen percent (15%) discount to the lesser of (i) (A) the VWAP average of the last 30 days ending on the closing of the Qualified Financing (or, in the event of multiple closings, the lowest VWAP average of the last 30 days ending on each closing of a Qualified Financing) in the event of a Maturity Date referred to in clause (b) of the definition thereof, or (B) the VWAP average of the last 30 days before the Maturity Date in the event of a Maturity Date referred to in clause (a) of the definition thereof, and (ii) eighteen cents (\$0.18).

**(b) Conversion upon Change of Control.** If a Change of Control transaction occurs prior to the Maturity Date, the outstanding principal and accrued and unpaid interest under the Note would, at the election of the holders of a majority of the outstanding principal of the Notes, be either (i) payable upon demand as of the closing of such Change of Control transaction or (ii) convertible into shares of the Common Stock immediately prior to such Change of Control transaction at a price per share equal to the lesser of (x) the VWAP average of the last 30 days before the date of consummation of the Change of Control, or (y) the per share consideration to be received by the holders of the Common Stock in such Change of Control transaction.

**(c) Cancellation.** Upon and as of the Maturity Date, this Note will be cancelled on the books and records of the Company and shall solely represent the right to receive the Conversion Shares.

### 3.2 Delivery of Securities Upon Conversion.

(a) As soon as is practicable after January 31, 2018 or an event pursuant to Section 3.1(b)(ii), the Company shall deliver to the Holder a certificate or certificates evidencing the Conversion Shares issuable to the Holder. Notwithstanding the foregoing and anything else to the contrary in this Note and the Subscription Agreements, if and to the extent the Company does not have enough authorized shares to issue Common Stock to the holders of notes in the Offering (the “*Current Offering Noteholders*”) and to all holders of existing convertible promissory notes of the Company that also convert upon a Qualified Financing (such holders of convertible promissory notes other than the Current Offering Noteholders, the “*Existing Noteholders*”), the Company shall first issue the necessary and applicable shares upon conversion to the Existing Noteholders and the Company shall issue the shares of Common Stock that would otherwise have been issued to the Current Offering Noteholders as of January 31, 2017 pursuant to Section 3.1(a), upon the earlier of (i) a reverse stock split of the Company’s Common Stock that allows for the issuance of the shares of Common Stock pursuant to this Note without violating the authorized share number of the Company and (ii) the approval of a proposal to increase the Company’s authorized shares of common stock at its next meeting of stockholders.

(b) The issuance of certificates for Conversion Shares upon conversion of this Note shall be made without charge to the Holder for any issuance tax in respect thereof or other cost incurred by the Company in connection with such conversion and the related issuance of securities. Upon conversion of this Note, the Company shall take all such actions as are necessary in order to ensure that the Conversion Shares so issued upon such conversion shall be validly issued, fully paid and nonassessable.

**3.3 Fractional Shares.** No fractional shares or scrip representing fractional shares shall be issued upon conversion of this Note. If any conversion of this Note would create a fractional share or a right to acquire a fractional share, the Company shall round to the nearest whole number.

## 4. STATUS; RESTRICTIONS ON TRANSFER.

**4.1 Status of Note.** This Note is a direct, general and unconditional obligation of the Company, and constitutes a valid and legally binding obligation of the Company, enforceable in accordance with its terms subject, as to enforcement, to bankruptcy, insolvency, reorganization and other similar laws of general applicability relating to or affecting creditors’ rights and to general principles of equity. This Note does not confer upon the Holder any right to vote or to consent or to receive notice as a stockholder of the Company, as such, in respect of any matters whatsoever, or any other rights or liabilities as a stockholder, prior to conversion hereof into Conversion Shares.

**4.2 Restrictions on Transferability.** This Note and any Conversion Shares issued with respect to this Note, have not been registered under the Securities Act, or under any state securities or so-called “blue sky laws,” and may not be offered, sold, transferred, hypothecated or otherwise assigned except (a) pursuant to a registration statement with respect to such securities which is effective under the Act or (b) upon receipt from counsel satisfactory to the Company of an opinion, which opinion is satisfactory in form and substance to the Company, to the effect that such securities may be offered, sold, transferred, hypothecated or otherwise assigned (i) pursuant to an available exemption from registration under the Act and (ii) in accordance with all applicable state securities and so-called “blue sky laws.” The Holder agrees to be bound by such restrictions on transfer. The Holder further consents that the certificates representing the Conversion Shares that may be issued with respect to this Note may bear a restrictive legend to such effect. In addition, this Note shall be subject to the restrictions on transfer set forth in Article III of the Subscription Agreement.



**4.3 COVENANTS.** In addition to the other covenants and agreements of the Company set forth in this Note, the Company covenants and agrees that so long as this Note shall be outstanding, if any one or more events occur which constitute or which, with the giving of notice or the lapse of time or both, would constitute an Event of Default or if the Holder shall demand payment or take any other action permitted upon the occurrence of any such Event of Default, the Company will forthwith give notice to the Holder, specifying the nature and status of the Event of Default or other event or of such demand or action, as the case may be.

**5. REMEDIES.**

**5.1 Events of Default.** “*Event of Default*” wherever used herein means any one of the following events:

(a) The Company shall fail to issue and deliver the Conversion Shares in accordance with Section 3;

(b) Default in the due and punctual payment of the principal of, or any other amount owing in respect of (including interest), this Note when and as the same shall become due and payable;

(c) Default in the performance or observance of any covenant or agreement of the Company in this Note (other than a covenant or agreement a default in the performance of which is specifically provided for elsewhere in this Section 6.1), and the continuance of such default for a period of 10 days after there has been given to the Company by the Holder a written notice specifying such default and requiring it to be remedied;

(d) The entry of a decree or order by a court having jurisdiction adjudging the Company as bankrupt or insolvent; or approving as properly filed a petition seeking reorganization, arrangement, adjustment or composition of or in respect of the Company under the Federal Bankruptcy Code or any other applicable federal or state law, or appointing a receiver, liquidator, assignee, trustee or sequestrator (or other similar official) of the Company or of any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 calendar days;

(e) The institution by the Company of proceedings to be adjudicated as bankrupt or insolvent, or the consent by it to the institution of bankruptcy or insolvency proceedings against it, or the filing by it of a petition or answer or consent seeking reorganization or relief under the Federal Bankruptcy Code or any other applicable federal or state law, or the consent by it to the filing of any such petition or to the appointment of a receiver, liquidator, assignee, trustee or sequestrator (or other similar official) of the Company or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors;

(f) The Company seeks the appointment of a statutory manager or proposes in writing or makes a general assignment or an arrangement or composition with or for the benefit of its creditors or any group or class thereof or files a petition for suspension of payments or other relief of debtors or a moratorium or statutory management is agreed or declared in respect of or affecting all or any material part of the indebtedness of the Company; or

(g) It becomes unlawful for the Company to perform or comply with its obligations under this Note.

**5.2 Effects of Default.** If an Event of Default occurs and is continuing, then and in every such case the Holder may declare this Note to be due and payable immediately, by a notice in writing to the Company, and upon any such declaration, the Company shall pay to the Holder the outstanding principal amount of this Note plus all accrued and unpaid interest through the date the Note is paid in full.

**5.3 Remedies Not Waived; Exercise of Remedies.** No course of dealing between the Company and the Holder or any delay in exercising any rights hereunder shall operate as a waiver by the Holder. No failure or delay by the Holder in exercising any right, power or privilege under this Note shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. By acceptance hereof, the Holder acknowledges and agrees that this Note is one of a series of Convertible Subordinated Promissory Notes of similar tenor issued by the Company (collectively, the “*Related Notes*”) and that upon the occurrence and during the continuance of any Event of Default, the holders of a majority in original principal amount of the Related Notes shall have the right to act on behalf of the holders of all such Notes in exercising and enforcing all rights and remedies available to all of such holders under this Note, including, without limitation, foreclosure of any judgment lien on any assets of the Company. By acceptance hereof, the Holder agrees not to independently exercise any such right or remedy without the consent of the holders of a majority in original principal amount of the Related Notes.

## 6. MISCELLANEOUS.

**6.1 Severability.** If any provision of this Note shall be held to be invalid or unenforceable, in whole or in part, neither the validity nor the enforceability of the remainder hereof shall in any way be affected.

**6.2 Notice.** Where this Note provides for notice of any event, such notice shall be given (unless otherwise herein expressly provided) in writing and either (a) delivered personally, (b) sent by certified, registered or express mail, postage prepaid or (c) sent by facsimile or other electronic transmission, and shall be deemed given when so delivered personally, sent by facsimile or other electronic transmission (confirmed in writing) or mailed. Notices shall be addressed, if to Holder, to its address as provided in the Subscription Agreement or, if to the Company, to its principal office.

**6.3 Governing Law.** This Note shall be governed by, and construed in accordance with, the laws of the State of Delaware (without giving effect to any conflicts or choice of law provisions that would cause the application of the domestic substantive laws of any other jurisdiction).

**6 . 4 Forum.** The Holder and the Company hereby agree that any dispute which may arise out of or in connection with this Note shall be adjudicated before a court of competent jurisdiction in the State of Delaware and they hereby submit to the exclusive jurisdiction of the courts of the State of Delaware, as well as to the jurisdiction of all courts to which an appeal may be taken from such courts, with respect to any action or legal proceeding commenced by either of them and hereby irrevocably waive any objection they now or hereafter may have respecting the venue of any such action or proceeding brought in such a court or respecting the fact that such court is an inconvenient forum.

**6 . 5 Headings.** The headings of the Articles and Sections of this Note are inserted for convenience only and do not constitute a part of this Note.

**6 . 6 Amendments.** This Note may be amended or waived only with the written consent of the Company and the holders of a majority in original aggregate principal amount of this Note and the Related Notes. Any such amendment or waiver shall be binding on all holders of the Notes, even if they do not execute such consent, amendment or waiver.

**6 . 7 No Recourse Against Others.** The obligations of the Company under this Note are solely obligations of the Company and no officer, employee or stockholder shall be liable for any failure by the Company to pay amounts on this Note when due or perform any other obligation.

**6 . 8 Assignment; Binding Effect.** This Note may be assigned by the Company without the prior written consent of the Holder. This Note shall be binding upon and inure to the benefit of both parties hereto and their respective permitted successors and assigns.

**Signature on the Following Page**

**In Witness Whereof**, the Company has caused this Note to be signed by its duly authorized officer on the date hereinabove written.

**Bionik Laboratories Corp.**

By: \_\_\_\_\_

Name: Eric Dusseux

Title: CEO

**Signature Page to Convertible Promissory Note**

---

**CERTIFICATION PURSUANT TO  
SECTION 302 OF  
THE SARBANES-OXLEY ACT OF 2002**

I, Eric Dusseux, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Bionik Laboratories Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report, our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Date: February 13, 2018

/s/ Eric Dusseux  
Eric Dusseux  
Chief Executive Officer  
(Principal Executive Officer)

---

**CERTIFICATION PURSUANT TO  
SECTION 302 OF  
THE SARBANES-OXLEY ACT OF 2002**

I, Leslie Markow, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Bionik Laboratories Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report, our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Date: February 13, 2018

/s/ Leslie Markow

Leslie Markow  
Chief Financial Officer  
(Principal Financial and Accounting Officer)

---

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Bionik Laboratories Corp. (the "Company") on Form 10-Q for the quarter ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Eric Dusseux, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: February 13, 2018

/s/ Eric Dusseux  
Eric Dusseux  
Chief Executive Officer  
(Principal Executive Officer)

---

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Bionik Laboratories Corp. (the "Company") on Form 10-Q for the quarter ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Leslie Markow, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: February 13, 2018

/s/ Leslie Markow

Leslie Markow

Chief Financial Officer

(Principal Financial and Accounting Officer)

---